

CURRICULUM VITAE

Justin R. Ortiz, MD, MS
Professor, Department of Medicine
Division of Geographic Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
University of Maryland School of Medicine

DATE May 22, 2026

CONTACT

Business Address: Center for Vaccine Development & Global Health
University of Maryland School of Medicine
685 W. Baltimore St., Room #480
Baltimore, MD 21201, USA

Business Phone: (410) 706-4946
Fax: (410) 706-6205
Email: jortiz@som.umaryland.edu

EDUCATION

1991-1995 Bachelor of Arts in English Literature, Dartmouth College
1995-1996 Non-degree post baccalaureate year, Colorado State University
1997-2002 Doctor of Medicine, University of California San Francisco (UCSF) School of
Medicine
2008-2012 Master of Science in Epidemiology, University of Washington (UW) School of
Public Health
2011 Certificate in Vaccinology, ADVAC Advanced Course of Vaccinology, Fondation
Mérieux and University of Geneva

POSTGRADUATE TRAINING

2002-2003 Internship, Categorical Internal Medicine, UCSF
2003-2005 Residency, Categorical Internal Medicine, UCSF
2005-2007 Epidemic Intelligence Service Officer, Influenza Division Centers for Disease
Control and Prevention (CDC)
2007-2008 Clinical Fellowship, Pulmonary and Critical Care Medicine, UW
2008-2010 Research Fellowship, Pulmonary and Critical Care Medicine, UW

CERTIFICATIONS

2005 Diplomat, American Board of Internal Medicine (Internal Medicine)
2010 Diplomat, American Board of Internal Medicine (Pulmonary Medicine)
Recertification 2023-2033
2011 Diplomat, American Board of Internal Medicine (Critical Care Medicine)

MEDICAL LICENSURE

2003 California (inactive)
2007 Washington (inactive)
2016 Colorado (inactive)
2017 Maryland (active)
2025 District of Columbia (active)

EMPLOYMENT HISTORY

Academic appointments

2010-2011 Acting Instructor of Medicine, Department of Medicine, UW
2011-2014 Assistant Professor of Medicine, Department of Medicine, UW
2012-2014 Assistant Professor of Global Health, Department of Global Health, UW
2014-2018 Affiliate Assistant Professor of Medicine, Department of Medicine, UW
2014-2019 Affiliate Assistant Professor of Global Health, Department of Global Health
2019-2020 Affiliate Associate Professor of Global Health, Department of Global Health
2017-2021 Associate Professor, Department of Medicine, UMSOM
2017-2018 Member, Institute for Global Health, UMSOM
2017-2018 Member, Center for Vaccine Development, UMSOM
2018-present Member, Center for Vaccine Development and Global Health, UMSOM
2021-present Professor, Department of Medicine, UMSOM

Other employment

1996-1997 AmeriCorps Vista Volunteer, San Luis Valley Christian Community Services, Alamosa, CO
2009 Consulting Scientist, Global Influenza Programme, World Health Organization (WHO), Geneva, Switzerland
2009-2010 Part-time physician, Swedish Hospital, Seattle, WA
2009-2013 Clinical Research Scientist, PATH, Seattle, WA
2014-2017 Medical Officer (P5 Rank), Initiative for Vaccine Research, WHO, Geneva, Switzerland
2019-2023 Consulting Scientist, Vanderbilt University School of Medicine, Nashville, TN
2021-2023 Consulting Scientist, UW School of Medicine, Seattle, WA

HONORS AND AWARDS

1995 C. Everett Koop Institute Primary Care Apprentice, Dartmouth Medical School
1996 Ronald E. McNair Post baccalaureate Achievement Program, Colorado State University
1996 Leadership Alliance Summer Research Early Identification Program, Brown University
1997 National Medical Fellowships Scholar, UCSF School of Medicine
1998 National Health Service Corps Primary Care Scholarship, UCSF
1999 University of Colorado Rural Multidisciplinary Scholarship, University of Colorado School of Medicine
2001 Arthur Ashe Program in AIDS Care, National Medical Fellowships, Harvard Medical School
2001 French American Foundation for Medical Research and Education Scholarship, UCSF
2004 Resident Teaching Fellowship, UCSF
2005 Nominated HHS Distinguished Secretary's Award for Katrina/Rita/Wilma Hurricane Response, CDC
2007 Silo Busters Honor Award, for effective inter-agency collaboration in response to the global threat of avian influenza (H5N1), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC
2009 Travel Grant, Annual Meeting of Infectious Diseases Society of America on Seasonal and Pandemic Influenza
2009 Scholarship, Summer Institute in Statistics and Modeling in Infectious Diseases, UW

- 2009 Lakshminarayan Fellow Fund Endowment Award, UW Division of Pulmonary and Critical Care Medicine (declined)
- 2009 John B. Coombs Research Award, UW Housestaff Association
- 2009-2011 Early Career Award, Thrasher Research Fund
- 2010 Minority Trainee Development Scholarship, American Thoracic Society
- 2010 UW Provost's Minority Faculty Recruitment Award
- 2010-2014 Harold Amos Medical Faculty Development Award, Robert Wood Johnson Foundation
- 2011 National Foundation for Infectious Diseases, Advanced Course of Vaccinology Scholarship
- 2015 American Thoracic Society Innovation in Fellowship Education Award for the creation of a Global Health Pathway at the UW Pulmonary and Critical Care Fellowship Training Program
- 2017 2016 Articles of the Year, American Journal of Epidemiology, and the Society for Epidemiologic Research, "Detectable Risks in Studies of the Fetal Benefits of Maternal Influenza Vaccination" (Bibliography: Article #37)
- 2020 Faculty Teacher of the Year, Division of Geographic Medicine, UMSOM
- 2021 University of Maryland, Baltimore Champion of Excellence Award for yeoman efforts to combat the SARS-CoV-2 virus awarded to the UMB Center for Vaccine Development and Global Health (CVD) faculty and staff
- 2023 UMSOM Clinical Research Article of the Year, "A Multi-Center, Controlled Human Infection Study of Influenza A (H1N1)pdm09 in Healthy Adults" (Bibliography: Article #137)

CLINICAL ACTIVITIES

- 2009-2010 Part-time intensivist, Swedish Hospital, Medical Intensive Care Unit, Seattle, WA
- 2009-2010 Part-time tuberculosis care provider, Public Health Seattle King County Tuberculosis Clinic, Seattle, WA
- 2010-2013 Attending physician, Medical Intensive Care Unit (MICU), UW Medical Center, Seattle, WA (8 weeks / year)
- 2010-2013 Attending physician, Pulmonary and Critical Care Medicine, Seattle Cancer Care Alliance (SCCA), Seattle, WA (8 weeks / year)
- 2018-2020 Attending physician, Travel Health Clinic, University of Maryland Medical Center, Baltimore, MD (2-4 clinics/month)

PROFESSIONAL ORGANIZATIONS

- 2007-present Fellow, American College of Physicians (elected fellow 2011)
- 2007-2014 Member, National Hispanic Medical Association
- 2008-present Member, American Thoracic Society
- 2008-2013 Member, Pan-African Thoracic Society
- 2009-present Fellow, American College of Chest Physicians (elected fellow 2012)
- 2010- present Member, International Society for Influenza and other Respiratory Virus Diseases

ADMINISTRATIVE SERVICE

Institutional service

UW School of Medicine

- 2010-2014 Organizing Committee Member, Global Health Pathway at the UW Pulmonary and Critical Care Fellowship Training Program

2011-2014 Associate Director and Founding Member, International Respiratory and Severe Illness Center (INTERSECT)

University of Maryland

2018 Member, CVD Assistant Professor Faculty Search Committee (UMSOM)
2018 Member, Meagan Fitzpatrick K01 Advisory Committee (UMSOM)
2018-2019 Scientific Advisory Committee, Frontiers in Vaccinology Conference (UMSOM)
2019-present Vaccinology post-doctoral fellowship (T32) interviewer, (UMSOM)
2019-2022 Organizer, CVD Influenza Interest Group (UMSOM)
2020-2022 Organizer, CVD/Department of Microbiology and Immunology COVID-19 Journal Club (UMSOM)
2019-present Internal Medicine Residency Interviewer (UMMC)
2020-2024 Co-Director, Collaborative Influenza Vaccine Innovation Centers Clinical Core (UMSOM)
2023 CVD Awards Committee (UMSOM)
2024-present Director, Collaborative Influenza Vaccine Innovation Centers Clinical Core (UMSOM)
2024-present Member, General Clinical Research Center (GCRC) Advisory Committee

Local service

2010-2013 American College of Physicians and Washington State Medical Association Representative to the Vaccine Advisory Committee, Washington State Department of Health
2011-2013 Liaison Member, Executive Council, Washington Chapter American College of Physicians
2013 Organizing Committee Member, World Pneumonia Day Commemoration, Seattle WA

National service

2005 Team Member, Mental health needs assessment in Louisiana evacuation centers. Hurricane Katrina Emergency Response. CDC, Mississippi and Louisiana, USA
2007 Expert Consultant, Council of State and Territorial Epidemiologists Avian Influenza Rapid Response Training, Multiple Sites, USA
2007 Writing Committee Member, Council of State and Territorial Epidemiologists. The Role of Public Health in a Multi-Agency Response to Avian Influenza in the United States
2009-2010 Member, International Lung Health Committee, American Thoracic Society
2010 Expert Consultant, CDC, Consultation on Pandemic Impact and Severity, Atlanta, GA, USA
2012 Grant Reviewer, CDC Special Emphasis Panel: "The Incidence of Community Associated Influenza and other Respiratory Infections in the United States (U01)". National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Atlanta, GA, USA
2018-2022 Writing Committee Member, CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents.
2019-2022 Independent Safety Monitor, National Institute of Allergy and Infectious Diseases (NIAID). Division of Microbiology and Infectious Diseases (DMID). Protocol: 12-

0100. A Phase I, Randomized Trial to Assess the Safety, Reactogenicity, and Immunogenicity of a Combination HTNV and PUUV DNA Vaccine Candidate Administered by Electroporation.
- 2019-2020 Independent Safety Monitor, PATH - Pharmaron Clinical Research. A Phase 2a Randomized, Single-Center, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Preliminary Efficacy of Oral iOWH032 Against Cholera Diarrhea in a Controlled Human Infection Mode.
- 2020-2022 Member, Respiratory Expert Working Group. NIAID Infectious Diseases Clinical Research Consortium
- 2020-2021 Member, Adaptive COVID-19 Treatment Trial Data Use Working Group
- 2020-2023 Independent Safety Monitor, US Army Medical Research and Development Command (USAMRDC). Protocol: DMID 12-0100. A Phase 1, Open-Label Clinical Trial with Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC) Assessment of Healthy U.S. Adults Previously Primed with Tetravalent Dengue Virus Purified Inactivated Vaccine (TDEN-PIV) and Boosted with Tetravalent Dengue Virus Live Attenuated Vaccine Formulation (TDEN LAV).
- 2020-2022 Member, NIH Human Epidemiology and Response to SARS-CoV-2 (HEROS) External Scientific Advisory Group

International service (general membership)

- 2006-present Ad hoc Reviewer, 6-8 manuscripts annually for peer-reviewed journals.
- 2006 Expert Consultant, Avian Influenza A (H5N1) Outbreak Alert and Response, African Regional Office of the WHO, Abuja, Nigeria
- 2006 Writing Committee Member, Seasonal and Novel Influenza Surveillance, Pan American Health Organization, Washington, DC, USA
- 2007 Expert Consultant, Seasonal and Novel Influenza Surveillance, Pan American Health Organization, Washington DC, USA
- 2007 Expert Consultant, Seasonal and Novel Influenza Surveillance, Pan American Health Organization, Mar del Plata, Argentina
- 2007 Expert Consultant, Seasonal and Novel Influenza Surveillance, Pan American Health Organization, Lima, Peru
- 2009 Expert Consultant, WHO Pandemic Influenza A (H1N1) Clinical Consultation, Washington DC, USA
- 2009-2013 Member, WHO Critical Care Working Group for Limited-Resource Settings, Geneva, Switzerland
- 2009 Expert Consultant, WHO Consultation on Public Health Research Agenda for Influenza, Geneva, Switzerland
- 2009 Expert Consultant, European Regional Office of the WHO (EURO) Pandemic Influenza A (H1N1), Copenhagen, Denmark
- 2010-2013 Member, WHO Influenza Epidemiological Working Group, Geneva, Switzerland
- 2010 Expert Consultant, WHO Consultation on Clinical Management of Influenza and Other Acute Respiratory Illness in Resource-Limited Settings, Geneva, Switzerland
- 2010-2012 Writing Committee, WHO Global Influenza Surveillance Manual Revision, Geneva, Switzerland
- 2011 Expert Consultant, WHO Consultation on Global Tools and Manual for Influenza Surveillance, Geneva, Switzerland
- 2011 Meeting Rapporteur, Bill and Melinda Gates Foundation Global Consultation on Maternal Influenza Immunization, London, UK
- 2011 Expert Consultant, Progress Review Workshop, WHO Public Health Research Agenda for Influenza, Geneva, Switzerland

2011	Expert Consultant, WHO/NIAID/INTERSECT Emerging Pathogens Clinical and Laboratory Network Collaborators Meeting, Philadelphia, USA
2012	Expert Consultant, WHO Workshop on Influenza Burden of Disease and Economic Analysis, Bali, Indonesia
2012	Meeting Rapporteur, Bill and Melinda Gates Foundation Expert Panel Consultation on Maternal Influenza Immunization, Johannesburg, South Africa
2012	Expert Consultant, Afriflu 2012 Workshop on Influenza Immunisation in Africa, Cape Town, South Africa
2012	Meeting Rapporteur, International Expert Meeting on Influenza Vaccines as a Tool to Estimate the Burden of Severe Influenza, Fondation Mérieux, Annecy, France
2012	Invited Participant, WHO/CDC International Meeting on Influenza Vaccine Effectiveness, Geneva, Switzerland
2012	Pulmonary Guideline Review Panel Member, WHO Integrated Management of Adolescent and Adult Illness (IMAI) District Clinician Manual
2013–present	Member, Brighton Collaboration
2013	Expert Consultant, Influenza Vaccine Investment Strategy, GAVI Alliance
2013	Expert Consultant, PATH Meeting on LAIV Vaccine Trials in Infants and Young Children, Washington, DC
2013	PhD Assessor, Michelle Groome, University of the Witwatersrand, School of Public Health. Interdisciplinary Doctoral Programme in Public and Population Health. Rotavirus vaccine and diarrhoeal morbidity in South Africa. Johannesburg, South Africa.
2013-2014	Member, Data Safety Monitoring Board, Microgen Scientific Industrial Company for Immunobiological Medicines of the Ministry of Health of the Russian Federation. Protocol: Reactogenicity, safety and immunogenicity of a live monovalent A/17/CALIFORNIA/66/395 (H2N2) influenza vaccine.
2015	Working Group Member, Global Alignment of Immunization safety Assessment in pregnancy (GAIA)
2016	Scientific Advisory Committee Member, PATH Maternal Pertussis Immunization Project
2016	Expert Consultant, Bill and Melinda Gates Foundation Pertussis Infant Burden of Disease Mini Symposium
2017	Expert Panelist, Healthcare Systems and Policies. Sustainable Local Production of Influenza Vaccines for Pandemic Preparedness. Geneva, Switzerland
2017-2018	Member, WHO Technical Working Group on Respiratory Syncytial Virus Vaccination During Pregnancy to Prevent Recurrent Childhood Wheezing
2017-2019	Member, Technical Expert Panel, PATH Advancing Maternal Immunization (AMI) Project
2017-present	Member, Global Burden of Disease Collaborator Network
2018	Expert Consultant, Influenza Vaccine Investment Strategy, GAVI Alliance
2018-present	Member Scientific Committee, Global Influenza Hospitalization Surveillance Network
2018-2020	Member, International Council on Adult Immunization
2018	Expert Consultant, International Federation on Ageing Vaccination and the At-risk Population of Adults with Heart and Lung Conditions' Expert Meeting, Stockholm, Sweden
2019	Expert Consultant, Immunisation for Life Summit. Washington DC. June 5-6
2018-2021	Member, Scientific Committee, Scientific Advisory Board on Real World Evidence & Seasonal Influenza Vaccines (Seqirus)

- 2020-2022 Member, Data Safety Monitoring Board Member: A Phase II Randomized, Double-Blind, Placebo-Controlled, Dose-De-Escalation Study of LMN-101 in Healthy Volunteers Challenged with *Campylobacter jejuni* (Advarra)
- 2020 Member, Acute Respiratory Distress Syndrome (ARDS) Case Definition Working Group, Brighton Collaboration/Safety Platform for Emergency vaccines (SPEAC) Project
- 2020-2021 Member, WHO COVID-19 Vaccine Effectiveness Technical Group
- 2021-present Member, Moderna Product Pipeline Advisory Board
- 2021-2022 Member, WHO RSV Vaccine and Monoclonal Antibody Value Profile Expert Group
- 2022-2023 Member, GSK RSV Cost Effectiveness Advisory Board
- 2023-2024 Member, Pfizer Advisory Committee of Influenza Experts (ACTIVE)
- 2023-2024 Member, Data Safety Monitoring Board Member: A randomized, double-blind, placebo-controlled trial assessing the efficacy of once-daily dosing of Travelan® in a controlled human infection model for ETEC (Advarra)
- 2024- present Member, Collaborative Influenza Vaccine Innovation Centers (CIVICs) Annual Meeting Planning Committee
- 2025-present Member, Data Safety Monitoring Board Member: A Two-stage, Phase 2b, Randomized, Double-blind, Placebo-controlled Safety, and Efficacy Study of ShigE_{TEC}, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old. [Allucent]
- 2025-present Member, Emmi UpToDate Patient Engagement Solutions Medical Advisory Board
- 2025-present Member, Safety Monitoring Committee, Eveliqre Biotechnologies GmbH. Protocol: EVQ2001. A Two-stage, Phase 2b, Randomized, Double-blind, Placebo-controlled Safety, and Efficacy Study of ShigE_{TEC}, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old.
- 2026 External PhD Examiner, Paula Couto, University of Edinburgh. Characterisation of the respiratory syncytial virus seasonality and its preventive strategies in the Americas as tools for health policies. Edinburgh, UK.

International service (leadership)

- 2009-2010 Team Lead, WHO Critical Care Training Working Group for Limited-Resource Settings, Geneva, Switzerland
- 2012 Co-Chair, WHO Informal Consultation on Influenza Disease Burden, Geneva, Switzerland
- 2014 Convener, WHO consultation on the development of a guidance for field evaluation of influenza vaccine effectiveness, February 20-21, 2014
- 2014 Convener, WHO meeting to assess live-attenuated influenza vaccines to prevent paediatric influenza disease in low and middle income countries, Geneva, Switzerland, December 16-17, 2014
- 2014 Convener, WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, May 5-7, 2014
- 2015 Convener, WHO technical consultation on maternal influenza immunization evidence and implementation, March 25-26, 2015
- 2015 Convener, WHO technical consultation on the effect of maternal influenza and influenza vaccination on the developing fetus: Montreal, Canada, September 30-October 1, 2015

- 2016 Convener, WHO meeting on repeated influenza vaccination and vaccine effectiveness, July 19, 2016
- 2016 Convener, WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses: Chicago, USA, August 23-24, 2016
- 2016 Convener, WHO Meeting on live attenuated influenza vaccine effectiveness, Geneva, Switzerland, September 20-21, 2016
- 2017 Convener, WHO meeting on immunization in older adults: Geneva, Switzerland, March 22-23, 2017
- 2019-2022 Steering Committee, Immunization for All Ages Initiative
- 2020-present Steering Committee, Council of Medical Specialty Societies. Prevention Of Disease, Disability, And Death Through Immunization and Control of Respiratory and Related Diseases
- 2020-2023 Co-Chair, American Thoracic Society Vaccines and Immunization Working Group
- 2021-present Co-Chair, American Thoracic Society Advancing Adult Immunization Initiative Steering Committee
- 2022 Convener, WHO Meeting to Assess RSV Prevention Cost Effectiveness in Low- and Middle-Income Countries. April 6-7, 2022
- 2025-present Co-Chair, Organizing Committee for the Options for the Control of Influenza 2026 International Conference to be held in Washington, DC in 2026
- 2026-present Co-Chair, Vaccine Guidance Review Panel, American Academy of Allergy, Asthma & Immunology / American Thoracic Society / American College of Chest Physicians / Society of Critical Care Medicine

International service (editorial boards)

- 2016-2019 Member, PLOS ONE Editorial Board
- 2016-2017 Member, WHO Editorial Board for Immunization Position Papers

TEACHING SERVICE

Clinical attending

- 2010-2013 Attending physician, Medical Intensive Care Unit (MICU), UW Medical Center, Seattle, WA. 1 fellow, 4 residents, 4 interns, 1-2 students 10 hours/day, 2 weeks/year.
- 2010-2013 Attending physician, Pulmonary and Critical Care Medicine, Seattle Cancer Care Alliance, Seattle, WA. 1 fellow 10 hours/day, 8 weeks/year.
- 2018-2020 Attending physician, UMSOM Travel Clinic, Baltimore, MD. 1 resident, 4 weeks/year.

Small group teaching

- 2008 Small Group Instructor, Human Biology 541 Respiratory Physiology, UW. 20-first year medical students-20 contact hours/year.
- 2017 Small Group instructor, Respiratory infections, Host Defenses and Infectious Diseases, UMSOM. 20-second year medical students-2 contact hours/year.
- 2019 Small Group instructor, Viral Respiratory Infections, Host Defenses and Infectious Diseases, UMSOM. 20-second year medical students-3 contact hours/year.
- 2019 Small Group instructor, Pneumonia, Host Defenses and Infectious Diseases, UMSOM. 20-second year medical students-3 contact hours/year.
- 2020 Small Group instructor, Pneumonia, Host Defenses and Infectious Diseases, UMSOM. 20-second year medical students-3 contact hours/year.

- 2020 Small Group instructor, Meningitis, Host Defenses and Infectious Diseases, UMSOM. 20-second year medical students-3 contact hours/year.
- 2020 Small Group instructor, Viral Respiratory Infections, Host Defenses and Infectious Diseases, UMSOM. 20-second year medical students-3 contact hours/year.

Lectures

- 2011, 2013 Lecturer, Global Health/Medicine 561 Tropical Medicine, UW. 40 first year medical students-2 contact hours/year.
- 2013 Lecturer, Epidemiology 532 Epidemiology of Infectious Diseases in Resource-limited Countries, UW. 40 graduate students-2 contact hours/year.
- 2013 Lecturer, Global Health 580 Global Health Doctoral Seminar: Biology, Systems and Measurement, UW. 40 graduate students-2 contact hours/year.
- 2018 Lecturer, UMB Internal Medicine-Pediatrics Residency Program Noon Conference. University of Maryland, Baltimore. 20 residents-1 contact hour.
- 2018 Panelist, Noon Conference, UMB School of Medicine. University of Maryland, Baltimore. 40 students-1 contact hour.
- 2019 Lecturer, Multi-departmental critical care fellows' lecture. Baltimore, Maryland.
- 2019-present Lecturer, PREV 627 Vaccinology graduate course– 3 hours, 15-20 students.
- 2019-present Lecturer, PREV 749 Infectious Disease Epidemiology graduate course– 3 hours, 15-20 students. 1 lecture/yr.
- 2020 Lecturer, First international European Interdisciplinary Council on Ageing e-learning course on antimicrobial resistance and the role of vaccines.
- 2022 Lecturer, University of Ottawa School of Public Health graduate course (Applied Research Methods in Public Health) –1 hour, 20 students.

High school mentoring

- 2024 Mentor to Janelle Ortiz, High School Student. One hour weekly clinical research training anticipated June 2024 through August 2024.

Medical student mentoring

- 2020 Mentor to Stephen Yu, MD, Medical Student, UMSOM. One hour weekly clinical research training over 26 weeks. (*Research product: publications #111, #120*)

Graduate student and post-doctoral research fellow mentoring

- 2014-2016 Mentor to Deshayne Fell, PhD, MPH, PhD student, McGill University. One hour weekly clinical research training over 78 weeks. (*Research product: publications #33, #47, #51, #60*)
- 2017-2019 Mentor to Corinne Aileen Riddell, PhD, Post-doctoral research fellow, McGill University. One hour monthly clinical research training over 2 years. (*Research product: publication #83*)
- 2018-2020 Mentor to Steven Brunwasser, PhD, Post-doctoral research fellow, Vanderbilt University. One hour monthly clinical research training over 2 years. (*Research product: publication #105, #133*)
- 2018-2022 Mentor to Amanda Driscoll, PhD, Post-doctoral research fellow, UMSOM. One hour monthly clinical research training over 2 years. (*Research product: publication #105, #110, #111, #117, #118, #120, #139*)
- 2018-2022 Mentor to Britney Snyder, PhD, Post-doctoral research fellow, Vanderbilt University. One hour monthly clinical research training over 2 years. (*Research product: publication #122, #133*)

- 2019-2020 Mentor to Rachel Laufer, MPH, MPH Graduate Student, University of Maryland Baltimore. One hour weekly clinical research training over 1 year. (*Research product: publication #117, #133, #134, ##139*)
- 2022-present Mentor to Chidozie Obichere, MPH(candidate), MPH Graduate Student, University of Maryland Baltimore. One hour weekly clinical research training over 78 weeks. (*Research product: MPH thesis completed and accepted*)
- 2023-2024 Mentor to Kaitlin Mason, BSN, RN, MPH(candidate), MPH Graduate Student, University of Maryland Baltimore. One hour weekly clinical research training over 52 weeks. (*Research product: MPH thesis completed and accepted*)
- 2024-present Mentor to Ibrahim Ahmed El-Imam, MD, PhD(candidate), PhD research rotation, University of Maryland Baltimore. One hour weekly clinical research training. (*Research ongoing*)

Resident and clinical fellow mentoring

- 2009 Mentor to Patricia Pavlinac, PhD, MS,, PhD student, UW. Three to five hours weekly clinical research training over the summer of 2009. (*Research product: publication research abstract*)
- 2011 Mentor to Andrea Dotson,, MSPH student, Johns Hopkins University. Three to five hours weekly clinical research training over the summer of 2011. (*Research product: internal PATH publication*)
- 2012-2013 Mentor to Kristina Rudd, MD, Internal Medicine Resident, UW. One hour weekly clinical research training over 52 weeks. (*Research product: publication #18*)
- 2011-2020 Mentor to Laura Hooper, MD, MPH, Internal Medicine Resident and Pulmonary & Critical Care Fellow, UW. Approximately once monthly clinical research training over 8 years. (*Research product: publication #23, #49, #81*)
- 2015 Mentor to Heather Carson, JD, PhD student, University of Texas, Galveston. Three to five hours weekly clinical research training over the summer of 2015. (*Research product: publication #127*)
- 2016-2020 Mentor to Ranjani Somayaji, MD, Post-doctoral research fellow, UW. Approximately once monthly clinical research training over 4 years. (*Research product: publication #53, #101*)
- 2019-2021 Mentor to Sarah Williams, MD, Post-doctoral research fellow, UMSOM. One hour weekly clinical research training over two years. (*Research product: publication #110, #111, #112, #120, #127, #137*)
- 2019-2022 Mentor to Jordan Braunfeld, MD, Internal Medicine Resident, UMSOM. One hour weekly clinical research training over 52 weeks. (*Research product: publication #127*)
- 2019-2021 Mentor to Meagan Deming, MD PhD, Infectious Diseases Fellow, UMSOM. One hour monthly clinical research training over 2 years. (*Research product: publication #106*)
- 2022-present Mentor to Elizabeth A.D. Hammershaimb, MD, Pediatric Infectious Diseases Fellow, UMSOM. Dr. Ortiz was on the fellow research advisory committee which met once quarterly through 2022. He has subsequently mentored Dr. Hammershaimb on two different research projects with one hour monthly clinical research training over 1 year.
- 2023-2025 Mentor to Andrew Gilmore, MD MPH, Post-doctoral research fellow, UMSOM. One hour weekly clinical research training over 52 weeks. Research product: (*Research product: publication #154*)
- 2023-present Mentor to Laura Hobbs, MD, Surgery Resident, UMSOM. One hour weekly clinical research training over 26 weeks. Research product: (*Research ongoing*)

- 2024-present Mentor to Allison LaRocco, MD, Post-doctoral research fellow, UMSOM. One hour weekly clinical research training beginning June 2024. Research product: *(Research ongoing)*
- 2024-present Mentor to Ian Galbreath, MD, Internal Medicine Resident, UMSOM. One hour weekly clinical research training beginning June 2024. Research product: *(Research ongoing)*
- 2024-present Mentor to Matthew Wolter, MD, Internal Medicine Resident, UMSOM. One hour weekly clinical research training beginning July 2025. Research product: *(Research ongoing)*
- 2024-present Mentor to Cihan Caglayan, MD MS, Post-doctoral research fellow, UMSOM. Anticipate One hour weekly clinical research training beginning June 2024 through June 2025. Research product: *(Research ongoing)*

Formal junior faculty mentoring

- 2018-2025 K01 Primary Mentor to Meagan Fitzpatrick, PhD, Assistant Professor, UMSOM.
- 2020-2022 Member, Elizabeth A.D. Hammershaimb Scholarship Oversight Committee, UMSOM Pediatrics Infectious Diseases
- 2024-2025 Faculty Mentoring Committee Member to Aisha Souquette, PhD, Research Associate, UMSOM

Curriculum development

- 2020-2022 Member, PREV 627 Vaccinology course curriculum committee
- 2009-2018 Lead (2009-2010), Member (2010-2018), Working group to develop the WHO short course on management of critically ill patients with acute respiratory infection
- 2010-2014 Organizing committee, Global Health Pathway at the University of Washington Pulmonary and Critical Care Fellowship Training Program University of Washington, Seattle, WA 2011-2014 Founding member and associate director, UW International Respiratory and Severe Illness Center (INTERSECT).
- 2022-2023 Steering Committee, GSK Vaccine Virtual Days. March 29-30, 2023
- 2024-2025 Steering Committee, France Foundation RSV CME Training.

GRANT SUPPORT

Active

- 2019-present Contract PI:
Collaborative Influenza Vaccine Innovation Centers (CIVICs), Clinical Core. The proposed research will advance the development of novel influenza vaccines through the design, execution and conduct of phase I and II clinical trials and challenge studies in diverse populations, and the establishment of a specimen repository for human samples for current and future scientific investigations.
HHS-NIH-NIAID-BAA2018, Contract No. 75N93019C00055
Subawards (role specified for each):
- Site PI, NIH/NIAID 75N93019C00055, *CIVICs SARS-CoV-2, Influenza, and Other Respiratory Pathogen Screening Protocol*
 - Site PI, NIH/NIAID 75N93019C00055, *Human H3N2 Influenza Challenge Study*
 - Protocol PI, NIH/NIAID 75N93019C00055, *Human Influenza H1N1 Challenge Study*
 - Site PI, NIH/NIAID 75N93019C00055, *CIVICs Adjuvanted QIV Older Adult Trial*

- 2022-present Protocol PI; PI: Matthias Schnell
Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever
Sponsor: National Institute of Allergy and Infectious Disease (NIAID),
HHSN272201700082C
- 2025-present PI:
ENA Respiratory Service Agreement
Sponsor: ENA Respiratory, Ltd.
- 2025-present PI:
Vaccination Practices of US Specialist Physicians
Sponsor: Pfizer Inc.
- 2025-present PI:
Phase II Randomized Clinical Trial
Sponsor: ENA Respiratory, Ltd.
- 2026-present Co-Investigator; PI: M Fitzpatrick
Vaccine Impact Modelling Consortium, RSV Modelling Group
Sponsor: GAVI, the Vaccine Alliance
- 2026-present PI:
Maryland Respiratory Pathogen Project (MRPP)
Development of an integrated hospital-based respiratory pathogen surveillance, clinical research, and sequencing platform linking UMMS clinical data, immunization records, and pathogen characterization
Sponsor: University of Maryland, Baltimore Targeted Pivoting Programmatic Research Grant

Completed funding

- 2008-2010 Fellow; PI: Len Hudson
Institutional Grant Supporting Research Training in Pulmonary and Critical Care Medicine
NHLBI, Respiratory Research Training Grant T32 HL007287
- 2008-2011 Co-Investigator; PI: JC Victor
Seasonal Influenza Vaccine Effectiveness in a Tropical Developing African Country
Center for Disease Control - 1U01IP000174
- 2008-2010 Co-Investigator; PI: KM Neuzil
Advancing seasonal and pandemic influenza vaccines project
Bill & Melinda Gates Foundation - 48805
- 2009 Co-Investigator; PI: J Fleming
Pilot Assessment of Indoor Air Pollution Exposure in Niakhar, Senegal
PATH Health Innovations Project Institutional Grant
- 2009-2010 PI
Influenza-Associated Adverse Outcomes of Pregnancy and in Newborns
John B. Coombs UWHA Research Award
- 2009-2011 PI
Assessment of Indoor Air Pollution as a Risk Factor for Influenza in Senegalese Children
Thrasher Research Fund Early Career Award - NR-0099
- 2010 Co-Investigator; PI: KM Neuzil
Landscape Analysis and Policy Pathway of Maternal Vaccination in Low Resource Settings
Bill & Melinda Gates Foundation - 17868

- 2010-2013 PI
Seasonal Influenza Vaccine Effectiveness in a Tropical Developing African Country
PATH Subagreement No. CDC.1421-03-08889-SUB under HHS/CDC (U01 IP000174-01)
- 2010-2014 PI
Development of Novel Tools to Estimate the Burden of Influenza-Associated Critical Illness
Robert Wood Johnson Harold Amos Medical Faculty Development Program - 67423
- 2011-2015 Co-Investigator; PI: JC Victor
Seasonal Influenza Vaccine Effectiveness in a Tropical Developing African Country
Center for Disease Control-1U01IP000476
- 2011 Co-Investigator; PI: TE West
2009 H1N1 Pandemic Influenza Management Literature Review
WHO
- 2011-2014 Co-Investigator; PI: SA Madhi
Influenza Vaccine Trial in Pregnant Women in South Africa
Subcontract of Bill & Melinda Gates Foundation (Grant OPP1002747)
- 2011-2013 PI
Live Attenuated Influenza Vaccine Efficacy in Bangladesh
PATH Subagreement GAT.387-05143-SUB under Bill & Melinda Gates Foundation (Grant 48805)
- 2012-2013 Co-Investigator; PI: G John-Stewart
Impact of Indoor Air Pollution on the Health of HIV-1 Infected Children in Kenya
NIH 2 R01 HD023412-21
- 2013-2017 PI
WHO/PATH Maternal Influenza Immunization Project
Bill & Melinda Gates Foundation - OPP1084288
- 2013-2017 PI
Building Routine Influenza Immunization Programs in Low-Resource Settings
Project US CDC - U01 CI000298
- 2015-2016 PI
Enhanced Collaboration between US NIH and WHO on Biomedical Research
National Institutes of Health - 5U01AI108543-01 Supplement
- 2017-2018 Co-Investigator; PI: DB Fell
Health outcomes in children of mothers who received influenza vaccination during pregnancy
Canadian Institutes of Health Research - AO1-151541
- 2017-2020 Co-Investigator; PI: KM Neuzil
A Phase II Study in Healthy Adults 19 Years and Older to Assess the Safety, Reactogenicity and Immunogenicity of a Sanofi Pasteur A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly with or without AS03 Adjuvant
NIH/NIAID Vaccine and Treatment Evaluation Units (VTEU) Task Area C1 - FY.2017.B8C12.0080 Influenza 17-0075
- 2017-2020 Co-Investigator; PI: KM Neuzil
A Phase II Study in Healthy Adults 19 Years and Older to Assess the Safety, Reactogenicity and Immunogenicity of Sequential or Simultaneous Intramuscular Administration of an AS03-adjuvanted A/H7N9 Inactivated Influenza Vaccine with Seasonal Trivalent Vaccine

- 2017-2020 NIH/NIAID Vaccine and Treatment Evaluation Units (VTEU) Task Area C2 -
FY.2017.B8C12.0080 Influenza 17-0077
Co-Investigator; PI: KM Neuzil
A Phase II Study to Assess the Safety, Reactogenicity and Immunogenicity of a
Single Dose of 2017 A/H7N9 Inactivated Influenza Vaccine (IIV) Administered
Intramuscularly with or without AS03 Adjuvant in 2013 A/H7N9 IIV Primed or
A/H7 IIV Naïve Subjects
- 2018-2019 NIH/NIAID Vaccine and Treatment Evaluation Units (VTEU) Task Area C7 -
FY.2017.B8C12.0080 Influenza 17-0090
Co-PI
Methodological considerations for studies to measure the association between
RSV LRTI and wheeze/asthma
WHO - 2018/829929
- 2018-2019 PI
Informing randomized control trials of respiratory syncytial virus vaccination
during pregnancy to prevent recurrent childhood wheezing: a sample size
analysis
WHO-2018/816365
- 2018-2019 PI
To advance the evidence base for influenza vaccine and adult immunization
policies and practice
WHO-2018/825465
- 2020 Site PI
A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and
Efficacy of Investigational Therapeutics for the Treatment of COVID-19 In
Hospitalized Adults
- 2020-2021 NIH/NIAID 3UM1AI148689-01S1
Co-PI
Informing Public Health Expectations and Policy for Next Generation RSV
Prevention Interventions in Mali: Modelling Studies to Estimate Health and
Economic Impact
PATH
- 2021– 2021 PI
Organization of a meeting on respiratory syncytial virus (RSV) health economics
and best-practices for conducting cost-effectiveness analyses
WHO
- 2020-2021 Co-PI
Informing Public Health Expectations and Policy for Next Generation RSV
Prevention Interventions in Mali: Modelling Studies to Estimate Health and
Economic Impact
PATH
- 2018-2021 Co-Investigator; PD: K Kotloff
NIH/NIAID HHSN272201300022I
Vaccine and Treatment Evaluation Unit (VTEU)
NIAID contract is for the evaluation of control measures against diseases other
than AIDS. The goal is to provide the necessary resources to conduct high-public
health priority phase I-IV clinical vaccine trials.
Subawards (Co-Investigator on each):
Task Area B-C 18-0011, Phase I Study of Adjuvanted Seasonal Influenza
Vaccine
Task Area B-C 18-0010, Natural History Challenge Study for Influenza

2022-2022	Task Order 16-0107, Phase I AV7909 Trial Co-Investigator; PI: M Fitzpatrick National Science Foundation, 2138192
2020-2023	RAPID: Identifying the drivers of optimal COVID-19 vaccine allocation PI Randomized Clinical Trial of a Novel Mucosal Recombinant H5 Influenza Vaccine with Nanoemulsion Adjuvant Followed by Parenteral Boost of Licensed Inactivated Influenza a H5N1 Vaccine NIH/NIAID U01AI148081
2019-2024	Co-Investigator; PI: JD Campbell A Phase 1, Randomized, Parallel-Group, Double-Blind Trial of AV7909 (Liquid) and Thermostable AV7909 (Lyophilized) in Healthy Adult Volunteers NIH/NAID HHSN272201300022I
2022-2024	PI Addressing unanticipated events for Intranasal Influenza A H5 Vaccine Trial NIH/NIAID U01AI148081
2023-2024	Co-Investigator; PI: Marcela Pasetti To collect mucosal and blood samples through an existing donor protocol NIH/NIAID
2024	Protocol PI: <i>“Vaccine and Treatment Evaluation Units (VTEU) Protocol Development and Implementation, Natural History Challenge Study for Influenza, Task Area B-C, 18-0010.B1C1.0120”</i>
2022-2025	NIAID Vaccine Treatment and Evaluation Unit, FY. 2018.B1C1.0120 Co-Investigator; PI: Donald Milton, Subaward PI: Wilbur Chen Evaluating Modes of Influenza Transmission (EMIT-2) using Innovative Technologies and Designs in Controlled Environments NIH/NIAID U19AI162130 (Subaward No. 107455-Z0447204)
2023-2025	PI <i>A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of DCFHP-Alum, A Spike-Functionalized Ferritin Nanoparticle Vaccine Targeting COVID-19, Co-formulated with Aluminum Hydroxide Adjuvant, in Health Adults in the United States</i> Sponsor: Vaccine Company, Inc.

PUBLICATIONS

Peer reviewed journal articles

1. Centers for Disease Control and Prevention (reported by Wang S, Dhara R, Brammer L, Postema A, Katz M, Uyeki T, Bresee J, Balish A, Wallis T, Hall H, Klimov A, Cox N, Ortiz JR*). Update: influenza activity – United States, October 2-December 3, 2005. MMWR Morb Mortal Wkly Rep. 2005 Dec 16;54(49):1256-9. PubMed PMID: 16357822. (**=first authorship*)
2. Centers for Disease Control and Prevention (reported by Bright RA, Shay D, Bresee J, Klimov A, Cox N, **Ortiz JR***). High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents-United States, 2005-06 influenza season. MMWR Morb Mortal Wkly Rep. 2006 Jan 20;55(2):44-6. PubMed PMID: 16424859.
3. **Ortiz JR**, Shay DK, Liedtke LA, Bresee JS, Strausbaugh LJ. A national survey of the Infectious Diseases Society of America Emerging Infections Network concerning

- neuraminidase inhibitor prescription practices and pandemic influenza preparations. *Clin Infect Dis*. 2006 Aug 15;43(4):494-7. Epub 2006 Jul 11. PubMed PMID: 16838240.
4. **Ortiz JR**, Wallis TR, Katz MA, Berman LS, Balish A, Lindstrom SE, et al. No evidence of avian influenza A (H5N1) among returning US travelers. *Emerg Infect Dis*. 2007 Feb;13(2):294-7. PubMed PMID: 17479895; PubMed Central PMCID: PMC2725853.
 5. **Ortiz JR***, Katz MA*, Mahmoud MN, Ahmed S, Bawa SI, Farnon EC, Sarki MB, Nasidi A, Ado MS, Yahaya AH, Joannis TM, Akpan RS, Vertefeuille J, Achenbach J, Breiman RF, Katz JM, Uyeki TM, Wali SS. Lack of Evidence for Avian-to-Human Transmission of Avian Influenza A (H5N1) Among Poultry Workers, Kano Nigeria, 2006. *J Infect Dis*. 2007 Dec 1;196(11):1685-91. Epub 2007 Oct 25. PubMed PMID: 18008254. (*=*Co-first authorship*)
 6. **Ortiz JR**, Kamimoto L, Aubert RE, Yao J, Shay DK, Bresee JS, Epstein RS. Oseltamivir prescribing in pharmacy-benefits database, United States, 2004-2005. *Emerg Infect Dis*. 2008 Aug;14(8):1280-3. doi: 10.3201/eid1408.080074. PubMed PMID: 18680656; PubMed Central PMCID: PMC2600408.
 7. Dickson RP, Martinez SM, **Ortiz JR**. A case of rapidly progressive necrotizing pneumonia caused by community-acquired methicillin-resistant *Staphylococcus aureus*. *Respir Care*. 2008 Sep;53(9):1223-6. PubMed PMID: 18718042.
 8. **Ortiz JR**, Sotomayor V, Uez OC, Oliva O, Bettels D, McCarron M, et al. Strategy to enhance influenza surveillance worldwide. *Emerg Infect Dis*. 2009 Aug;15(8):1271-8. doi: 10.3201/eid1508.081422. PubMed PMID: 19751590; PubMed Central PMCID: PMC2815958.
 9. **Ortiz JR**, Neuzil KM, Victor JC, Wald A, Aitken ML, Goss CH. Influenza-associated cystic fibrosis pulmonary exacerbations. *Chest*. 2010 Apr;137(4):852-60. doi: 10.1378/chest.09-1374. Epub 2009 Dec 4. PubMed PMID: 19965953; PubMed Central PMCID: PMC2851556.
 10. **Ortiz JR**, Neuzil KM, Victor JC, Aitken ML, Goss CH. Predictors of influenza vaccination in the Cystic Fibrosis Foundation patient registry, 2006 through 2007. *Chest*. 2010 Dec;138(6):1448-55. doi: 10.1378/chest.10-0356. Epub 2010 May 21. PubMed PMID: 20495106; PubMed Central PMCID: PMC2998208.
 11. **Ortiz JR**, Zhou H, Shay DK, Neuzil KM, Fowlkes AL, Goss CH. Monitoring influenza activity in the United States: a comparison of traditional surveillance systems with Google Flu Trends. *PLoS One*. 2011 Apr 27;6(4):e18687. PubMed PMID: 21556151; PubMed Central PMCID: PMC3083406.
 12. **Ortiz JR**, Englund JA, Neuzil KM. Influenza vaccine for pregnant women in resource-constrained countries: A review of the evidence to inform policy decisions. *Vaccine*. 2011 Jun 15;29(27):4439-52. Epub 2011 May 6. PubMed PMID: 21550377.
 13. **Ortiz JR**, Lafond KE, Wong TA, Uyeki TM. Pandemic influenza in Africa, lessons learned from 1968: a systematic review of the literature. *Influenza Other Respir Viruses*. 2012 Jan;6(1):11-24. doi: 10.1111/j.1750-2659.2011.00257.x. Epub 2011 May 3. PMID: 21668669; PMCID: PMC3175329.
 14. Reed C, Madhi SA, Klugman KP, Kuwanda L, **Ortiz JR**, Finelli L, et al. Development of the Respiratory Index of Severity in Children (RISC) score among young children with respiratory infections in South Africa. *PLoS One*. 2012;7(1):e27793. doi: 10.1371/journal.pone.0027793. Epub 2012 Jan 4. PubMed PMID: 22238570; PubMed Central PMCID: PMC3251620.
 15. Neuzil KM, Tsvetnitsky V, Nyari LJ, Bright RA, Boslego JW, on behalf of PATH's Influenza Vaccine Project team (**Ortiz JR**, member). PATH Influenza Vaccine Project: accelerating the development of new influenza vaccines for low-resource countries. *Expert Rev Vaccines*. 2012 Aug; 11(8):939-947. PubMed PMID: 23002975.

16. Horne DJ, Campo M, **Ortiz JR**, Oren E, Arentz M, Crothers K, et al. Association between Smoking and Latent Tuberculosis in the U.S. Population: An Analysis of the National Health and Nutrition Examination Survey. *PLoS One*. 2012;7(11):e49050. doi: 10.1371/journal.pone.0049050. Epub 2012 Nov 8. PubMed PMID: 23145066.
17. **Ortiz JR**, Neuzil KM, Ahonkhai VI, Gellin BG, Salisbury DM, Read JS, et al. Translating vaccine policy into action: A report from the Bill & Melinda Gates Foundation Consultation on the prevention of maternal and early infant influenza in resource-limited settings. *Vaccine*. 2012 Sep 28. pii: S0264-410X(12)01345-X. doi: 10.1016/j.vaccine.2012.09.034. [Epub ahead of print] PubMed PMID: 23026690.
18. **Ortiz JR***, Rudd KE*, Clark DV, Jacob ST, West TE. Clinical research during a public health emergency: a systematic review of severe pandemic influenza management. *Crit Care Med*. 2013 May;41(5):1345-52. doi: 10.1097/CCM.0b013e3182771386. Review. PubMed PMID: 23399939. (*=*Co-first authorship*)
19. **Ortiz JR**, Jacob ST, West TE. Clinical care for severe influenza and other severe illness in resource-limited settings: the need for evidence and guidelines. *Influenza Other Respir Viruses*. 2013 Sep;7 Suppl 2:87-92. doi: 10.1111/irv.12086. Review. PubMed PMID: 24034491.
20. **Ortiz JR**, Neuzil KM, Rue TC, Zhou H, Shay DK, Cheng PY, et al. Population-based incidence estimates of influenza-associated respiratory failure hospitalizations, 2003 to 2009. *Am J Respir Crit Care Med*. 2013 Sep 15;188(6):710-5. doi: 10.1164/rccm.201212-2341OC. PubMed PMID: 23855650.
21. Reed C, Bruden D, Byrd KK, Veguilla V, Bruce M, Hurlburt D, Wang D, Holiday C, Hancock K, **Ortiz JR**, Klejka J, Katz JM, Uyeki TM. Characterizing wild bird contact and seropositivity to highly pathogenic avian influenza A (H5N1) virus in Alaskan residents. *Influenza Other Respir Viruses*. 2014 May 14. doi: 10.1111/irv.12253. [Epub ahead of print] PubMed PMID: 24828535.
22. Madhi SA, Cutland CL, Kuwanda L, Weinberg A, Hugo A, Jones S, Adrian PV, van Niekerk N, Treurnicht F, **Ortiz JR**, Venter M, Violari A, Neuzil KM, Simões EA, Klugman KP, Nunes MC; Maternal Flu Trial (Matflu) Team. Influenza vaccination of pregnant women and protection of their infants. *N Engl J Med*. 2014 Sep 4;371(10):918-31. doi: 10.1056/NEJMoa1401480. PubMed PMID: 25184864.
23. **Ortiz JR**, Neuzil KM, Shay DK, Rue TC, Neradilek MB, Zhou H, et al. The burden of influenza-associated critical illness hospitalizations. *Crit Care Med*. 2014 Nov;42(11):2325-32. doi: 10.1097/CCM.0000000000000545. PMID: 25148596; PMCID: PMC4620028.
24. **Ortiz JR**, Neuzil KM, Cooke CR, Neradilek MB, Goss CH, Shay DK. Influenza pneumonia surveillance among hospitalized adults may underestimate the burden of severe influenza disease. *PLoS One*. 2014 Nov 25;9(11):e113903. doi: 10.1371/journal.pone.0113903. eCollection 2014. PubMed PMID: 25423025; PubMed Central PMCID: PMC4244176.
25. World Health Organization (**Ortiz JR** Editorial Board). Meeting of the Strategic Advisory Group of Experts on immunization, April 2015: Conclusions and Recommendations. *Wkly Epidemiol Rec*. 2015 May 29;90(22):261-78. English, French. PubMed PMID: 26027016.
26. Goss LB, **Ortiz JR**, Okamura DM, Hayward K, Goss CH. Significant Reductions in Mortality in Hospitalized Patients with Systemic Lupus Erythematosus in Washington State from 2003 to 2011. *PLoS One*. 2015 Jun 18;10(6):e0128920. doi: 10.1371/journal.pone.0128920. eCollection 2015. PubMed PMID: 26087254; PubMed Central PMCID: PMC4473009.
27. **Ortiz JR**, Goswami D, Lewis KDC, Sharmeen AT, Mostaq A, Rahman M, Rahman MZ, Feser J, Neuzil KM, Brooks WA. Safety of Russian-backbone seasonal trivalent, live-

- attenuated influenza vaccine in a phase II randomized placebo-controlled clinical trial among children in urban Bangladesh. *Vaccine*. 2015 Jun 26;33(29):3415-21. doi: 10.1016/j.vaccine.2015.04.048. Epub 2015 Apr 24. PMID: 25917680.
28. Omer SB, Richards JL, Madhi SA, Tapia MD, Steinhoff MC, Aqil AR, et al. for BMGF Supported Maternal Influenza Immunization Trials Investigators Group (**Ortiz JR** member). Three randomized trials of maternal influenza immunization in Mali, Nepal, and South Africa: Methods and expectations. *Vaccine*. 2015 Jun 19. pii: S0264-410X(15)00750-1. doi: 10.1016/j.Vaccine.2015.05.077. [Epub ahead of print] Review. PubMed PMID: 26095508.
 29. Marangu D, Kovacs S, Walson J, Bonhoeffer J, **Ortiz JR**, John-Stewart G, et al. Wheeze as an adverse event in pediatric vaccine and drug randomized controlled trials: A systematic review. *Vaccine*. 2015 Oct 5;33(41):5333-5341. doi: 10.1016/j.vaccine.2015.08.060. Epub 2015 Aug 28. PMID: 26319071; PMCID: PMC4743983.
 30. Lambach P, Alvarez AM, Hirve S, **Ortiz JR**, Hombach J, Verweij M, et al. Considerations of strategies to provide influenza vaccine year round. *Vaccine*. 2015 Aug 28. pii: S0264-410X(15)01164-0. doi: 10.1016/j.Vaccine.2015.08.037. [Epub ahead of print] Review. PubMed PMID: 26319745.
 31. Munoz FM, Eckert LO, Katz MA, Lambach P, **Ortiz JR**, Bauwens J, et al. Key terms for the assessment of the safety of vaccines in pregnancy: Results of a global consultative process to initiate harmonization of adverse event definitions. *Vaccine*. 2015 Nov 25;33(47):6441-52. doi: 10.1016/j.vaccine.2015.07.112. Epub 2015 Sep 19. PMID: 26387433; PMCID: PMC8243724.
 32. Fulton TR, Narayanan D, Bonhoeffer J, **Ortiz JR**, Lambach P, Omer SB. A systematic review of adverse events following immunization during pregnancy and the newborn period. *Vaccine*. 2015 Nov 25;33(47):6453-65. doi: 10.1016/j.vaccine.2015.08.043. Epub 2015 Sep 26. PMID: 26413879; PMCID: PMC8290429.
 33. Savitz DA, Fell DB, **Ortiz JR**, Bhat N. Does influenza vaccination improve pregnancy outcome? Methodological issues and research needs. *Vaccine*. 2015 Aug 26. pii: S0264-410X(15)01168-8. doi: 10.1016/j.Vaccine.2015.08.041. [Epub ahead of print] PubMed PMID: 26319740.
 34. Lambach P, Hombach J, **Ortiz JR**. A global perspective of maternal influenza immunization. *Vaccine*. 2015 Nov 25;33(47):6376-9. doi: 10.1016/j.vaccine.2015.08.036. Epub 2015 Aug 28. PMID: 26319068; PMCID: PMC8243657.
 35. Cox NJ, Hickling J, Jones R, Rimmelzwaan GF, Lambert LC, Boslego J, Rudenko L, Yeolekar L, Robertson JS, Hombach J, **Ortiz JR**. Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5-7 May 2014. *Vaccine*. 2015 Nov 27;33(48):6503-10. doi: 10.1016/j.vaccine.2015.10.014. Epub 2015 Oct 23. PMID: 26478203; PMCID: PMC8218335.
 36. Nunes MC, Cutland CL, Dighero B, Bate J, Jones S, Hugo A, et al.; Matflu Team (**Ortiz JR** member, published as "**Ortiz JR**"). Kinetics of Hemagglutination-Inhibiting Antibodies Following Maternal Influenza Vaccination Among Mothers With and Those Without HIV Infection and Their Infants. *J Infect Dis*. 2015 Dec 15;212(12):1976-87. doi: 10.1093/infdis/jiv339. Epub 2015 Jun 16. PubMed PMID: 26080370; PubMed Central PMCID: PMC4655859. Erratum for Nunes et al. (Correcting **Ortiz JR** name spelling) *J Infect Dis*. 2019 Sep 13;220(8):1392. doi: 10.1093/infdis/jiz293. Erratum for: *J Infect Dis*. 2015 Dec 15;212(12):1976-87. PMID: 31269213; PMCID: PMC7325324.
 37. Hutcheon JA, Fell DB, Jackson ML, Kramer MS, **Ortiz JR**, Savitz DA, et al. Detectable Risks in Studies of the Fetal Benefits of Maternal Influenza Vaccination. *Am J Epidemiol*.

- 2016 Aug 1;184(3):227-32. doi: 10.1093/aje/kww048. Epub 2016 Jun 30. PubMed PMID: 27365363; PubMed Central PMCID: PMC4967598.
38. Cassidy C, MacDonald NE, Steenbeek A, **Ortiz JR**, Zuber PL, Top KA. A global survey of adverse event following immunization surveillance systems for pregnant women and their infants. *Hum Vaccin Immunother*. 2016 Aug 2;12(8):2010-2016. Epub 2016 May 9. PubMed PMID: 27159639; PubMed Central PMCID: PMC4994761.
 39. Beeler JA, Lambach P, Fulton TR, Narayanan D, **Ortiz JR**, Omer SB. A systematic review of ethical issues in vaccine studies involving pregnant women. *Hum Vaccin Immunother*. 2016 Aug 2;12(8):1952-1959. Epub 2016 May 31. PubMed PMID: 27246403; PubMed Central PMCID: PMC4994733.
 40. Top KA, Arkell C, Scott H, McNeil SA, Mannerfeldt J, **Ortiz JR**, et al. Effect of package insert language on health-care providers' perceptions of influenza vaccination safety during pregnancy. *Lancet Glob Health*. 2016 Oct;4(10):e690-1. doi: 10.1016/S2214-109X(16)30182-6. PMID: 27633430; PMCID: PMC8274327.
 41. Mertz D, Fadel SA, Lam PP, Tran D, Srigley JA,, **Ortiz JR**, et al. Herd effect from influenza vaccination in non-healthcare settings: a systematic review of randomised controlled trials and observational studies. *Euro Surveill*. 2016 Oct 20;21(42):30378. doi: 10.2807/1560-7917.ES.2016.21.42.30378. PMID: 27784531; PMCID: PMC5291154.
 42. Proveaux T, Lambach P, **Ortiz JR**, Hombach J, Halsey NA. Review of prescribing information for influenza vaccines for pregnant and lactating women. *Vaccine*. 2016 Oct 26;34(45):5406-5409. doi: 10.1016/j.vaccine.2016.08.042. Epub 2016 Aug 29. PMID: 27595450; PMCID: PMC8218337.
 43. **Ortiz JR**, Perut M, Dumolard L, Wijesinghe PR, Jorgensen P, Ropero AM, et al. A global review of national influenza immunization policies: Analysis of the 2014 WHO/UNICEF Joint Reporting Form on immunization. *Vaccine*. 2016 Oct 26;34(45):5400-5405. doi: 10.1016/j.Vaccine.2016.07.045. Epub 2016 Sep 16. Review. PubMed PMID: 27646030; PubMed Central PMCID: PMC5357765.
 44. Verweij M, Lambach P, **Ortiz JR**, Reis A. Maternal immunisation: ethical issues. *Lancet Infect Dis*. 2016 Dec;16(12):e310-e314. doi: 10.1016/S1473-3099(16)30349-8. Epub 2016 Sep 20. PMID: 27663129; PMCID: PMC8243647.
 45. Brooks WA, Zaman K, Lewis KD, **Ortiz JR**, Goswami D, Feser J, et al. Efficacy of a Russian-backbone live attenuated influenza vaccine among young children in Bangladesh: a randomised, double-blind, placebo-controlled trial. *Lancet Glob Health*. 2016 Dec;4(12):e946-e954. doi: 10.1016/S2214-109X(16)30200-5. PubMed PMID: 27746226; PubMed Central PMCID: PMC5118223.
 46. Victor JC, Lewis KD, Diallo A, Niang MN, Diarra B, Dia N, **Ortiz JR**, Widdowson MA, Feser J, Hoagland R, Emery SL, Lafond KE, Neuzil KM. Efficacy of a Russian-backbone live attenuated influenza vaccine among children in Senegal: a randomised, double-blind, placebo-controlled trial. *Lancet Glob Health*. 2016 Dec;4(12):e955-e965. doi: 10.1016/S2214-109X(16)30201-7. PubMed PMID: 27746224; PubMed Central PMCID: PMC5118222.
 47. Fell DB, Savitz DA, Kramer MS, Gessner BD, Katz MA, Knight M, Luteijn JM, Marshall H, Bhat N, Gravett MG, Skidmore B, **Ortiz JR**. Maternal influenza and birth outcomes: systematic review of comparative studies. *BJOG*. 2017 Jan;124(1):48-59. doi: 10.1111/1471-0528.14143. Epub 2016 Jun 6. Review. PubMed PMID: 27264387; PubMed Central PMCID: PMC5216449.
 48. Mertz D, Geraci J, Winkup J, Gessner BD, **Ortiz JR**, Loeb M. Pregnancy as a risk factor for severe outcomes from influenza virus infection: A systematic review and meta-analysis of observational studies. *Vaccine*. 2017 Jan 23;35(4):521-528. doi: 10.1016/j.Vaccine.2016.12.012. Epub 2016 Dec 23. Review. PubMed PMID: 28024955; PubMed Central PMCID: PMC5359513.

49. Hooper LG, Dieye Y, Ndiaye A, Diallo A, Fan VS, Neuzil KM, **Ortiz JR**. Estimating pediatric asthma prevalence in rural Senegal: A cross-sectional survey. *Pediatr Pulmonol*. 2017 Mar;52(3):303-309. doi: 10.1002/ppul.23545. Epub 2016 Aug 23. PubMed PMID: 27551858.
50. World Health Organization (**Ortiz JR** member WHO Editorial Board for Immunization Position Papers). Dengue vaccine: WHO position paper, July 2016 -recommendations. *Vaccine*. 2017 Mar 1;35(9):1200-1201. doi:10.1016/j.Vaccine.2016.10.070. Epub 2017 Feb 6. PubMed PMID: 28185744.
51. Fell DB, Bhutta ZA, Hutcheon JA, Karron RA, Knight M, Kramer MS, Monto AS, Swamy GK, **Ortiz JR**, Savitz DA. Report of the WHO technical consultation on the effect of maternal influenza and influenza vaccination on the developing fetus: Montreal, Canada, September 30-October 1, 2015. *Vaccine*. 2017 Apr 25;35(18):2279-2287. doi: 10.1016/j.vaccine.2017.03.056. Epub 2017 Mar 24. PMID: 28343772; PMCID: PMC8274346.
52. Katz MA, Gessner BD, Johnson J, Skidmore B, Knight M, Bhat N, Marshall H, Horne DJ, **Ortiz JR**, Fell DB. Incidence of influenza virus infection among pregnant women: a systematic review. *BMC Pregnancy Childbirth*. 2017 May 30;17(1):155. doi: 10.1186/s12884-017-1333-5. Erratum in: *BMC Pregnancy Childbirth*. 2017 Jun 19;17(1):192. PubMed PMID: 28558777; PubMed Central PMCID: PMC5450114.
53. Somayaji R, Goss CH, Khan U, Neradilek M, Neuzil KM, **Ortiz JR**. Cystic Fibrosis Pulmonary Exacerbations Attributable to Respiratory Syncytial Virus and Influenza: A Population-Based Study. *Clin Infect Dis*. 2017 Jun 15;64(12):1760-1767. doi: 10.1093/cid/cix203. PMID: 28329304; PMCID: PMC5848232.
54. Madhi SA, Nunes MC, Weinberg A, Kuwanda L, Hugo A, Jones S, van Niekerk N, **Ortiz JR**, Neuzil KM, Klugman KP, Simões EAF, Cutland CL; Maternal Flu Trial (Matflu) Team. Contribution of Serologic Assays in the Evaluation of Influenza Virus Infection Rates and Vaccine Efficacy in Pregnant Women: Report From Randomized Controlled Trials. *Clin Infect Dis*. 2017 Jun 15;64(12):1773-1779. doi: 10.1093/cid/cix241. PubMed PMID: 28369198; PubMed Central PMCID: PMC5447878.
55. Fell DB, Johnson J, Mor Z, Katz MA, Skidmore B, Neuzil KM, **Ortiz JR**, Bhat N. Incidence of laboratory-confirmed influenza disease among infants under 6 months of age: a systematic review. *BMJ Open*. 2017 Sep 7;7(9):e016526. doi: 10.1136/bmjopen-2017-016526. Erratum in: *BMJ Open*. 2018 Jan 30;8(1):e016526corr1. PMID: 28882916; PMCID: PMC5595206.
56. **Ortiz JR**, Neuzil KM. Influenza immunization of pregnant women in resource-constrained countries: an update for funding and implementation decisions. *Curr Opin Infect Dis*. 2017 Oct;30(5):455-462. doi: 10.1097/QCO.0000000000000392. PubMed PMID: 28777109.
57. Nunes MC, Cutland CL, Jones S, Downs S, Weinberg A, **Ortiz JR**, et al. Efficacy of maternal influenza vaccination against all-cause lower respiratory tract infection hospitalizations in young infants: Results from a randomized controlled trial. *Clin Infect Dis*. 2017 Oct 1;65(7):1066-1071. doi: 10.1093/cid/cix497. PMID: 28575286; PMCID: PMC5848298.
58. World Health Organization (**Ortiz JR** Editorial Board). WHO position on the use of fractional doses - June 2017, addendum to vaccines and vaccination against yellow fever WHO: Position paper - June 2013. *Vaccine*. 2017 Oct 13;35(43):5751-5752. doi: 10.1016/j.vaccine.2017.06.087. Epub 2017 Jul 6. PubMed PMID: 28689653.
59. Neuzil KM, Bresee JS, de la Hoz F, Johansen K, Karron RA, Krishnan A, Madhi SA, Mangtani P, Spiro DJ, **Ortiz JR**; WHO Preferred Product Characteristics for Next-Generation Influenza Vaccines Advisory Group. Data and product needs for influenza immunization programs in low- and middle-income countries: Rationale and main

- conclusions of the WHO preferred product characteristics for next-generation influenza vaccines. *Vaccine*. 2017 Oct 13;35(43):5734-5737. doi: 10.1016/j.Vaccine.2017.08.088. Epub 2017 Sep 20. PubMed PMID: 28893473.
60. Fell DB, Azziz-Baumgartner E, Baker MG, Batra M, Beauté J, Beutels P, Bhat N, Bhutta ZA, Cohen C, De Mucio B, Gessner BD, Gravett MG, Katz MA, Knight M, Lee VJ, Loeb M, Luteijn JM, Marshall H, Nair H, Pottie K, Salam RA, Savitz DA, Serruya SJ, Skidmore B, **Ortiz JR**; WHO taskforce to evaluate influenza data to inform vaccine impact and economic modelling. Influenza epidemiology and immunization during pregnancy: Final report of a World Health Organization working group. *Vaccine*. 2017 Oct 13;35(43):5738-5750. doi: 10.1016/j.vaccine.2017.08.037. Epub 2017 Sep 1. PMID: 28867508; PMCID: PMC8274347.
 61. World Health Organization (**Ortiz JR** Editorial Board). Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations. *Vaccine*. 2017 Oct 13;35(43):5753-5755. doi: 10.1016/j.vaccine.2017.05.069. Epub 2017 Jun 5. PubMed PMID: 28596091.
 62. Rotrosen E, Zaman K, Feser J, **Ortiz JR**, Goswami D, Sharmeen AT, et al. Influenza Among Young Children in Bangladesh: Clinical Characteristics and Outcomes From a Randomized Clinical Trial. *Clin Infect Dis*. 2017 Nov 13;65(11):1914-1920. doi: 10.1093/cid/cix674. PMID: 29028980; PMCID: PMC5850015.
 63. Pecenka C, Munthali S, Chunga P, Levin A, Morgan W, Lambach P, Bhat N, Neuzil KM, **Ortiz JR**, Hutubessy R. Maternal Influenza Immunization in Malawi: Piloting a Maternal Influenza Immunization Program Costing Tool by examining a prospective program. *PLoS One*. 2017 Dec 27;12(12):e0190006. doi: 10.1371/journal.pone.0190006. PMID: 29281710; PMCID: PMC5744963.
 64. Malosh RE, Martin ET, **Ortiz JR**, Monto AS. The risk of lower respiratory tract infection following influenza virus infection: A systematic and narrative review. *Vaccine*. 2018 Jan 2;36(1):141-147. doi: 10.1016/j.vaccine.2017.11.018. Epub 2017 Nov 20. PMID: 29157959; PMCID: PMC5736984.
 65. World Health Organization (**Ortiz JR** Editorial Board). Diphtheria vaccine: WHO position paper, August 2017 - Recommendations. *Vaccine*. 2018 Jan 4;36(2):199-201. doi: 10.1016/j.vaccine.2017.08.024. Epub 2017 Aug 16. PubMed PMID: 28822645.
 66. Fitzner J, Qasmieh S, Mounts AW, Alexander B, Besselaar T, Briand S, Brown C, Clark S, Dueger E, Gross D, Hauge S, Hirve S, Jorgensen P, Katz MA, Mafi A, Malik M, McCarron M, Meerhoff T, Mori Y, Mott J, Olivera MTDC, **Ortiz JR**, Palekar R, Rebelo-de-Andrade H, Soetens L, Yahaya AA, Zhang W, Vandemaele K. Revision of clinical case definitions: influenza-like illness and severe acute respiratory infection. *Bull World Health Organ*. 2018 Feb 1;96(2):122-128. doi: 10.2471/BLT.17.194514. Epub 2017 Nov 27. PubMed PMID: 29403115; PubMed Central PMCID: PMC5791775.
 67. **Ortiz JR**, Hickling J, Jones R, Donabedian A, Engelhardt OG, Katz JM, et al. Report on WHO meeting on immunization in older adults: Geneva, Switzerland, 22-23 March 2017. *Vaccine*. 2018 Jan 11. pii: S0264-410X(17)31782-6. doi: 10.1016/j.vaccine.2017.12.029. [Epub ahead of print] PubMed PMID: 29336923.
 68. Aguado TM, Barratt J, Beard JR, Blomberg BB, Chen WH, Hickling J, Hyde TB, Jit M, Jones R, Poland GA, Friede M, **Ortiz JR**. Report on WHO meeting on immunization in older adults: Geneva, Switzerland, 22-23 March 2017. *Vaccine*. 2018 Feb 8;36(7):921-931. doi: 10.1016/j.vaccine.2017.12.029. Epub 2018 Jan 12. PMID: 29336923; PMCID: PMC5865389.
 69. Baxter RP, Lewis N, Fireman B, Hansen J, Klein NP, **Ortiz JR**. Live Attenuated Influenza Vaccination Before 3 Years of Age and Subsequent Development of Asthma: A 14-year Follow-up Study. *Pediatr Infect Dis J*. 2018 May;37(5):383-386. doi: 10.1097/INF.0000000000001783. Erratum in: *Pediatr Infect Dis J*. 2018 Jun;37(6):611. PubMed PMID: 28914750; PubMed Central PMCID: PMC5847407.

70. World Health Organization (**Ortiz JR** Editorial Board). Cholera vaccine: WHO position paper, August 2017 - Recommendations. *Vaccine*. 2018 Jun 7;36(24):3418-3420. doi:10.1016/j.vaccine.2017.09.034. Epub 2018 Mar 17. PubMed PMID: 29555219.
71. World Health Organization (**Ortiz JR** Editorial Board). Tetanus vaccines: WHO position paper, February 2017 - Recommendations. *Vaccine*. 2017 Apr 17. pii: S0264-410X(17)30228-1. doi: 10.1016/j.Vaccine.2017.02.034. [Epub ahead of print] PubMed PMID: 28427847.
72. Debellut F, Hendrix N, **Ortiz JR**, Lambach P, Neuzil KM, Bhat N, et al. Forecasting demand for maternal influenza immunization in low- and lower-middle-income countries. *PLoS One*. 2018 Jun 22;13(6):e0199470. doi: 10.1371/journal.pone.0199470. eCollection 2018. PubMed PMID: 29933402; PubMed Central PMCID: PMC6014664.
73. Fleming JA, Baltrons R, Rowley E, Quintanilla I, Crespín E, Ropero AM, **Ortiz JR**, Lambach P, Neuzil KM, Stepanchak M, Hombach J, Bhat N. Implementation of maternal influenza immunization in El Salvador: Experiences and lessons learned from a mixed-methods study. *Vaccine*. 2018 May 30. pii: S0264-410X(18)30762-X. doi: 10.1016/j.vaccine.2018.05.096. [Epub ahead of print] PubMed PMID: 29859803.
74. Diaz JV, **Ortiz JR**, Lister P, Shindo N, Adhikari NKJ. Development of a short course on management of critically ill patients with acute respiratory infection and impact on clinician knowledge in resource-limited ICUs. *Influenza Other Respir Viruses*. 2018 Sep;12(5):649-655. doi: 10.1111/irv.12569. Epub 2018 May 26. PMID: 29727522; PMCID: PMC6086848.
75. GBD 2016 Alcohol Collaborators (**Ortiz JR** member). Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*. 2018 Sep 22;392(10152):1015-1035. doi: 10.1016/S0140-6736(18)31310-2. Epub 2018 Aug 23. PubMed PMID: 30146330; PubMed Central PMCID: PMC6148333.
76. Diallo A, Victor JC, Kanesa-thasan N, Feser J, **Ortiz JR**, Ndiaye M, et al. Immunogenicity and safety of MF59-adjuvanted and full dose unadjuvanted trivalent inactivated influenza vaccines among vaccine-naïve children in a randomized clinical trial in rural Senegal. *Vaccine*. 2018 Oct 15;36(43):6424-6432. doi: 10.1016/j.vaccine.2018.08.032. Epub 2018 Sep 14. PMID: 30224199; PMCID: PMC6327321.
77. GBD 2016 Lower Respiratory Infections Collaborators (**Ortiz JR** member). Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016, *Lancet Infect Dis*. 2018 Nov;18(11):1191-1210. doi: 10.1016/S1473-3099(18)30310-4. Epub 2018 Sep 19. PubMed PMID: 30243584; PubMed Central PMCID: PMC6202443.
78. GBD 2017 SDG Collaborators (**Ortiz JR** member). Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018 Nov 10;392(10159):2091-2138. doi: 10.1016/S0140-6736(18)32281-5. Epub 2018 Nov 8. PubMed PMID: 30496107; PubMed Central PMCID: PMC6227911.
79. GBD 2017 Causes of Death Collaborators (**Ortiz JR** member). Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018 Nov 10;392(10159):1736-1788. doi: 10.1016/S0140-6736(18)32203-7. Epub 2018 Nov 8. PubMed PMID: 30496103; PubMed Central PMCID: PMC6227606.
80. GBD 2017 Mortality Collaborators (**Ortiz JR** member). Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the

- Global Burden of Disease Study 2017. *Lancet*. 2018 Nov 10;392(10159):1684-1735. doi: 10.1016/S0140-6736(18)31891-9. Epub 2018 Nov 8. PubMed PMID: 30496102; PubMed Central PMCID: PMC6227504.
81. Hooper LG, Dieye Y, Ndiaye A, Diallo A, Fan VS, Neuzil KM, **Ortiz JR**. Traditional Cooking Practices and Preferences for Stove Features among Women in Rural Senegal: Guidance for Improved Cookstove Design and Interventions. *PLoS One*. 2018 Nov 20;13(11):e0206822. doi: 10.1371/journal.pone.0206822. eCollection 2018. PubMed PMID: 30458001; PubMed Central PMCID: PMC6245512.
 82. GBD 2016 Meningitis Collaborators (**Ortiz JR** member). Global, regional, and national burden of meningitis, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol*. 2018 Dec;17(12):1061-1082. doi: 10.1016/S1474-4422(18)30387-9. Epub 2018 Nov 13. PubMed PMID: 30507391; PubMed Central PMCID: PMC6234314.
 83. Riddell CA, Bhat N, Bont LJ, Dupont WD, Feikin DR, Fell DB, Gebretsadik T, Hartert TV, Hutcheon JA, Karron RA, Nair H, Reiner RC, Shi T, Sly PD, Stein RT, Wu P, Zar HJ, **Ortiz JR** for the WHO Technical Working Group on Respiratory Syncytial Virus Vaccination During Pregnancy to Prevent Recurrent Childhood Wheezing. Informing randomized clinical trials of respiratory syncytial virus vaccination during pregnancy to prevent recurrent childhood wheezing: a sample size analysis. *Vaccine*. 2018 Dec 18;36(52):8100-8109. doi: 10.1016/j.vaccine.2018.10.041. Epub 2018 Nov 22. PMID: 30473186; PMCID: PMC6288067.
 84. GBD 2017 Influenza Collaborators (**Ortiz JR** member). Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017. *Lancet Respir Med*. 2019 Jan;7(1):69-89. doi: 10.1016/S2213-2600(18)30496-X. Epub 2018 Dec 12. PMID: 30553848; PMCID: PMC6302221.
 85. World Health Organization (**Ortiz JR** Editorial Board). Measles vaccines: WHO position paper, April 2017 - Recommendations. *Vaccine*. 2017 Jul 28. pii: S0264-410X(17)30974-X. doi: 10.1016/j.vaccine.2017.07.066. [Epub ahead of print] PubMed PMID: 28760612.
 86. World Health Organization (**Ortiz JR** Editorial Board). Hepatitis B vaccines: WHO position paper, July 2017 - Recommendations. *Vaccine*. 2019 Jan 7;37(2):223-225. doi: 10.1016/j.vaccine.2017.07.046. Epub 2017 Jul 22. PubMed PMID: 28743487.
 87. Katz MA, Marangu D, Attia EF, Bauwens J, Bont LJ, Bulatovic A, Crane J, Doroshenko A, Ebruke BE, Edwards KM, Fortuna L, Jagelaviciene A, Joshi J, Kemp J, Kovacs S, Lambach P, Lewis KDC, **Ortiz JR**, Simões EAF, Turner P, Tagbo BN, Vaishnavi V, Bonhoeffer J; Brighton Collaboration Wheeze Working Group. Acute wheeze in the pediatric population: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. *Vaccine*. 2017 May 5. pii: S0264-410X(17)30163-9. doi: 10.1016/j.vaccine.2017.01.083. [Epub ahead of print] PubMed PMID: 28483201.
 88. **Ortiz JR**, Neuzil KM. Influenza Immunization in Low and Middle-Income Countries: Preparing for Next-Generation Influenza Vaccines. *J Infect Dis*. 2019 Apr 8;219(Supplement_1):S97-S106. doi: 10.1093/infdis/jiz024. PubMed PMID: 30715348.
 89. Kochhar S, Edwards KM, Ropero Alvarez AM, Moro PL, **Ortiz JR**. Introduction of new vaccines for immunization in pregnancy - Programmatic, regulatory, safety and ethical considerations. *Vaccine*. 2019 May 31;37(25):3267-3277. doi: 10.1016/j.vaccine.2019.04.075. Epub 2019 May 6. PMID: 31072733; PMCID: PMC6771279.
 90. **Ortiz JR**, Neuzil KM. Influenza vaccine programs for children in low- and middle-income countries: current status and way forward. *Expert Rev Vaccines*. 2019 Jul;18(7):711-724. doi: 10.1080/14760584.2019.1635462. Epub 2019 Jul 5. PMID: 31226895.

91. Walsh LK, Donelle J, Dodds L, Hawken S, Wilson K, Benchimol EI, Chakraborty P, Guttman A, Kwong JC, MacDonald NE, **Ortiz JR**, Sprague AE, Top KA, Walker MC, Wen SW, Fell DB. Health outcomes of young children born to mothers who received 2009 pandemic H1N1 influenza vaccination during pregnancy: retrospective cohort study. *BMJ*. 2019 Jul 10;366:l4151. doi: 10.1136/bmj.l4151. PMID: 31292120; PMCID: PMC6614795.
92. Fleming JA, Munthali A, Ngwira B, Kadzandira J, Jamili-Phiri M, **Ortiz JR**, et al. Maternal immunization in Malawi: A mixed methods study of community perceptions, programmatic considerations, and recommendations for future planning. *Vaccine*. 2019 Jul 26;37(32):4568-4575. doi: 10.1016/j.vaccine.2019.06.020. PMID: 31319932; PMCID: PMC6642336.
93. Mertz D, Lo CK, Lytvyn L, **Ortiz JR**, Loeb M; FLURISK-INVESTIGATORS. Pregnancy as a risk factor for severe influenza infection: an individual participant data meta-analysis. *BMC Infect Dis*. 2019 Aug 2;19(1):683. doi: 10.1186/s12879-019-4318-3. PMID: 31375073; PMCID: PMC6679491.
94. Brickley EB, Wright PF, Khalenkov A, Feser J, Neuzil KM, **Ortiz JR**, et al. The effect of pre-existing immunity on virus detection and immune responses in a phase II randomized trial of a Russian-backbone live attenuated influenza vaccine in Bangladeshi children. *Clin Infect Dis*. 2019 Aug 16;69(5):786-794. doi: 10.1093/cid/ciy1004. PMID: 30481269; PMCID: PMC6695513.
95. Lewis KDC*, **Ortiz JR***, Rahman MZ, Levine MZ, Katz JM, Fry AM, et al. Immunogenicity and Viral Shedding of a Seasonal Trivalent Live Attenuated Influenza Virus Vaccine among Children in Bangladesh. *Clin Infect Dis*. 2019 Aug 16;69(5):777-785. doi: 10.1093/cid/ciy1003. PMID: 30481272; PMCID: PMC6695509. (*=*Co-first authorship*)
96. Simões EAF, Nunes MC, Carosone-Link P, Madimabe R, **Ortiz JR**, Neuzil KM, et al. Trivalent influenza vaccination randomized control trial of pregnant women and adverse fetal outcomes. *Vaccine*. 2019 Aug 23;37(36):5397-5403. doi: 10.1016/j.vaccine.2019.07.024. Epub 2019 Jul 19. PMID: 31331777; PMCID: PMC6694200.
97. Diallo A, Diop OM, Diop D, Niang MN, Sugimoto JD, **Ortiz JR**, et al. Effectiveness of Seasonal Influenza Vaccination in Children in Senegal During a Year of Vaccine Mismatch: A Cluster-randomized Trial. *Clin Infect Dis*. 2019 Oct 30;69(10):1780-1788. doi: 10.1093/cid/ciz066. PMID: 30689757; PMCID: PMC6821165.
98. GBD 2017 Lower Respiratory Infections Collaborators (**Ortiz JR** member). Quantifying risks and interventions that have affected the burden of lower respiratory infections among children younger than 5 years: an analysis for the Global Burden of Disease Study 2017. *Lancet Infect Dis*. 2020 Jan;20(1):60-79. doi: 10.1016/S1473-3099(19)30410-4. Epub 2019 Oct 31. PMID: 31678026; PMCID: PMC7185492.
99. Nunes MC, Cutland CL, Moultrie A, Jones S, **Ortiz JR**, Neuzil KM, et al. Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial. *Lancet HIV*. 2020 Feb;7(2):e91-e103. doi: 10.1016/S2352-3018(19)30322-4. Epub 2020 Jan 3. PMID: 31911146; PMCID: PMC7167514.
100. Driscoll AJ, Arshad SH, Bont L, Brunwasser SM, Cherian T, Englund JA, Fell DB, Hammitt LL, Hartert TV, Innis BL, Karron RA, Langley GE, Mulholland EK, Munywoki PK, Nair H, **Ortiz JR**, Savitz DA, Scheltema NM, Simões EAF, Smith PG, Were F, Zar HJ, Feikin DR. Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting.

- Vaccine. 2020 Mar 4;38(11):2435-2448. doi: 10.1016/j.vaccine.2020.01.020. Epub 2020 Jan 20. PMID: 31974017; PMCID: PMC7049900.
101. Somayaji R, Neradilek MB, Szpiro AA, Lofy KH, Jackson ML, Goss CH, Duchin JS, Neuzil KM, **Ortiz JR**. Effects of Air Pollution and Other Environmental Exposures on Estimates of Severe Influenza Illness, Washington, USA. *Emerg Infect Dis*. 2020 May;26(5):920–9. doi: 10.3201/eid2605.190599. PMID: 32310747; PMCID: PMC7181929.
 102. Omer SB, Clark DR, Madhi SA, Tapia MD, Nunes MC, Cutland CL et al.; BMGF Supported Maternal Influenza Immunization Trials Investigators Group (**Ortiz JR** member). Efficacy, duration of protection, birth outcomes, and infant growth associated with influenza vaccination in pregnancy: a pooled analysis of three randomised controlled trials. *Lancet Respir Med*. 2020 Jun;8(6):597-608. doi: 10.1016/S2213-2600(19)30479-5. PMID: 32526188; PMCID: PMC7284303.
 103. GBD 2017 Chronic Respiratory Disease Collaborators (**Ortiz JR** member). The Prevalence and Attributable Health Burden of Chronic Respiratory Diseases from 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Respir Med*. 2020 Jun;8(6):585-596. doi: 10.1016/S2213-2600(20)30105-3. PMID: 32526187; PMCID: PMC7284317.
 104. Lina B, Georges A, Burtseva E, Nunes M, Andrew MK, Ruiz-Palacios GM, Feng L, Kyncl J, Vanhems P, Ferdinands JM, **Ortiz JR**, Paget PG, and Reiner RC on behalf of the GIHSN. Complicated hospitalization due to influenza: results from the Global Hospital Influenza Network for the 2017-2018 season. *BMC Infect Dis*. 2020 Jul 2;20(1):465. doi: 10.1186/s12879-020-05167-4. PMID: 32615985; PMCID: PMC7330273.
 105. Brunwasser SM, Donovan BM, Driscoll AJ, Fell DB, Savitz DA, Feikin DR, Skidmore B, Bhat N, Bont LJ, Dupont WD, Wu P, Gebretsadik T, Holt PG, Zar HJ, **Ortiz JR**, Hartert TV#. Assessing the strength of evidence for a causal effect of respiratory syncytial virus lower respiratory tract infections on subsequent wheezing illness: a systematic review and meta-analysis. *Lancet Respir Med*. 2020 Aug;8(8):795-806. doi: 10.1016/S2213-2600(20)30109-0. Erratum in: *Lancet Respir Med*. 2021 Jan;9(1):e10. PMID: 32763206; PMCID: PMC7464591.
 106. Niang M, Deming ME, Goudiaby D, Diop OM, Dia N, Diallo A, **Ortiz JR**, Diop D, Lewis KDC, Lafond KE, Widdowson MA, Victor JC, Neuzil KM. Immunogenicity of seasonal inactivated influenza and inactivated polio vaccines among children in Senegal: Results from a cluster-randomized trial. *Vaccine*. 2020 Nov 3;38(47):7526-7532. doi: 10.1016/j.vaccine.2020.09.059. Epub 2020 Oct 2. PMID: 33012603; PMCID: PMC7936169.
 107. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, et al. for the ACTT-1 Study Group Members (**Ortiz JR** member). Remdesivir for the Treatment of Covid-19 — Final Report [published online ahead of print, 2020 October 8]. *N Engl J Med*. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8. PMID: 32445440; PMCID: PMC7262788.
 108. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al; COVE Study Group (**Ortiz J** member). Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30. PMID: 33378609; PMCID: PMC7787219.
 109. Fell DB, Dimitris MC, Hutcheon JA, **Ortiz JR**, Platt RW, Regan AK, et al. Guidance for design and analysis of observational studies of fetal and newborn outcomes following COVID-19 vaccination during pregnancy. *Vaccine*. 2021 Apr 1;39(14):1882-1886. doi: 10.1016/j.vaccine.2021.02.070. Epub 2021 Mar 2. PMID: 33715900; PMCID: PMC7923848.

110. Williams SR, Driscoll AJ, LeBuhn HM, Chen WH, Neuzil KM, **Ortiz JR**. National routine adult immunisation programmes among World Health Organization Member States: an assessment of health systems to deploy COVID-19 vaccines. *Euro Surveill*. 2021 Apr;26(17):2001195. doi: 10.2807/1560-7917.ES.2021.26.17.2001195. PMID: 33928899; PMCID: PMC8086245.
111. **Ortiz JR**, Robertson J, Hsu JS, Yu SL, Driscoll AJ, Williams SR, et al. The potential effects of deploying SARS-Cov-2 vaccines on cold storage capacity and immunization workload in countries of the WHO African Region. *Vaccine*. 2021 Apr 8;39(15):2165-2176. doi: 10.1016/j.vaccine.2021.02.037. Epub 2021 Feb 19. PMID: 33744049; PMCID: PMC7894202.
112. Serazin NA, Edem B, Williams SR, **Ortiz JR**, Kawade A, Das MK, et al. Acute respiratory distress syndrome (ARDS) as an adverse event following immunization: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. *Vaccine*. 2021 Jan 28:S0264-410X(21)00092-X. doi: 10.1016/j.vaccine.2021.01.053. Epub ahead of print. PMID: 33583673; PMCID: PMC7843093.
113. Mehrabadi A, Dodds L, MacDonald NE, Top KA, Benchimol EI, Kwong JC, **Ortiz JR**, Sprague A, Walsh LK, Wilson K, Fell DB. Early childhood health outcomes following in utero exposure to seasonal influenza vaccine: a population-based cohort study. Association of Maternal Influenza Vaccination During Pregnancy With Early Childhood Health Outcomes. *JAMA*. 2021 Jun 8;325(22):2285-2293. doi: 10.1001/jama.2021.6778. PMID: 34100870; PMCID: PMC8188273.
114. Niang MN, Sugimoto JD, Diallo A, Diarra B, **Ortiz JR**, Feser J, et al. Estimates of inactivated influenza vaccine effectiveness among children in Senegal: results from two annual cluster-randomized controlled trials from 2010 through 2011-12. *Clin Infect Dis*. 2021 Jun 15;72(12):e959-e969. doi: 10.1093/cid/ciaa1689. PMID: 33165566; PMCID: PMC8204774.
115. Patel MK, Bergeri I, Bresee JS, Cowling BJ, Crowcroft NS, Fahmy K, Hirve S, Kang G, Katz MA, Lanata CF, L'Azou Jackson M, Joshi S, Lipsitch M, Mwenda JM, Nogareda F, Orenstein WA, **Ortiz JR**, Pebody R, Schrag SJ, Smith PG, Srikantiah P, Subissi L, Valenciano M, Vaughn DW, Verani JR, Wilder-Smith A, Feikin DR. Evaluation of post-introduction COVID-19 Vaccine Effectiveness: Summary of interim guidance of the World Health Organization. *Vaccine*. 2021 Jul 5;39(30):4013-4024. doi: 10.1016/j.vaccine.2021.05.099. Epub 2021 Jun 1. PMID: 34119350; PMCID: PMC8166525.
116. Colombo CJ, Colombo RE, Maves RC, Branche AR, Cohen SH, Elie MC, George SL, Jang H, Kalil AC, Lindholm DA, Mularski RA, **Ortiz JR**, Tapson V, Liang CJ on behalf of the ACTT-1 Study Group. Performance Analysis of the National Early Warning Score and Modified Early Warning Score in the Adaptive COVID-19 Treatment Trial Cohort. *Crit Care Explor*. 2021 Jul 13;3(7):e0474. doi: 10.1097/CCE.0000000000000474. PMID: 34278310; PMCID: PMC8280088.
117. Laufer RS, Driscoll AJ, Baral R, Buchwald AG, Campbell JD, Coulibaly F, Diallo F, Dombia M, Feikin DR, Galvani AP, Haidara F, Kotloff KL, Keita AM, Neuzil KN, Orenstein E, Pecenka C, Sow S, Tapia MD, **Ortiz JR**#, Fitzpatrick MC#. Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions. *Vaccine*. 2021 Aug 16;39(35):5037-5045. doi: 10.1016/j.vaccine.2021.06.086. Epub 2021 Jul 26. PMID: 34325934; PMCID: PMC8377743.
118. Driscoll AJ, **Ortiz JR**, Hartert TV, Riddell CA. Recalibrating public health expectations of respiratory syncytial virus lower respiratory tract illness prevention on chronic respiratory

- disease. *Vaccine*. 2021 Aug 31;39(37):5257-5258. doi: 10.1016/j.vaccine.2021.07.074. Epub 2021 Aug 6. PMID: 34366146; PMCID: PMC9927872.
119. El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. (**Ortiz J** member, note not indexed by **Ortiz JR**). Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. *N Engl J Med*. 2021 Nov 4;385(19):1774-1785. doi: 10.1056/NEJMoa2113017. Epub 2021 Sep 22. PMID: 34551225; PMCID: PMC8482810.
 120. **Ortiz JR**, Yu SL, Driscoll AJ, Williams SR, Robertson J, Hsu JS, et al. The Operational Feasibility of Vaccination Programs Targeting Influenza Risk Groups in the World Health Organization (WHO) African and South-East Asian Regions. *Clin Infect Dis*. 2022 Jan 29;74(2):227-236. doi: 10.1093/cid/ciab393. PMID: 33949661; PMCID: PMC8800189.
 121. Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, et al. Study Group (**Ortiz J** member, note not indexed by **Ortiz JR**). Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. *N Engl J Med*. 2022 Feb 10;386(6):531-543. doi: 10.1056/NEJMoa2116185. Epub 2021 Dec 15. PMID: 34910859; PMCID: PMC8693692.
 122. Snyder BM, Patterson MF, Gebretsadik T, Wu P, Ding T, Lee RL, Edwards KM, Somerville LA, Braciale TJ, **Ortiz JR**, Hartert TV. Validation of International Classification of Diseases criteria to identify severe influenza hospitalizations. *Influenza Other Respir Viruses*. 2022 May;16(3):371-375. doi: 10.1111/irv.12931. Epub 2022 Jan 4. PMID: 34984832; PMCID: PMC8983891.
 123. Imran M, Puig-Barberà J, **Ortiz JR**, Fisher L, O'Brien D, Bonafede M, et al. Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019-2020 Influenza Season. *Open Forum Infect Dis*. 2022 Apr 2;9(5):ofac167. doi: 10.1093/ofid/ofac167. PMID: 35493131; PMCID: PMC9045943.
 124. Boikos C, Imran M, De Lusignan S, **Ortiz JR**, Patriarca PA, Mansi JA. Integrating Electronic Medical Records and Claims Data for Influenza Vaccine Research. *Vaccines (Basel)*. 2022 May 6;10(5):727. doi: 10.3390/vaccines10050727. PMID: 35632483; PMCID: PMC9143116.
 125. **Ortiz JR**, Spearman PW, Goepfert PA, Cross K, Creech C, Chen WH, et al. Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial. *Vaccine*. 2022 May 20;40(23):3253-3262. doi: 10.1016/j.vaccine.2022.03.055. Epub 2022 Apr 22. PMID: 35465983; PMCID: PMC9897630.
 126. Boikos C, McGovern I, Molrine D, **Ortiz JR**, Puig-Barberà J, Haag M. Review of Analyses Estimating Relative Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Three Consecutive US Influenza Seasons. *Vaccines (Basel)*. 2022 Jun 3;10(6):896. doi: 10.3390/vaccines10060896. PMID: 35746504; PMCID: PMC9228909.
 127. Braunfeld JB, Carson HN, Williams SR, Schwartz LM, Neuzil KM, **Ortiz JR**. Clinical endpoints to inform vaccine policy: A systematic review of outcome measures from pediatric influenza vaccine efficacy trials. *Vaccine*. 2022 Jul 30;40(32):4339-4347. doi: 10.1016/j.vaccine.2022.06.028. Epub 2022 Jun 16. PMID: 35717265.
 128. Imran M, **Ortiz JR**, McLean HQ, Fisher L, O'Brien D, Bonafede M, et al. Relative Effectiveness of Cell-based Versus Egg-based Quadrivalent Influenza Vaccines in Children and Adolescents in the United States During the 2019-2020 Influenza Season. *Pediatr Infect Dis J*. 2022 Sep 1;41(9):769-774. doi: 10.1097/INF.0000000000003620. Epub 2022 Jun 4. PMID: 35797705; PMCID: PMC9359763.
 129. Boikos C, McGovern I, **Ortiz JR**, Puig-Barberà J, Versage E, Haag M. Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine over Three Consecutive

- Influenza Seasons in the United States. *Vaccines* (Basel). 2022 Sep 2;10(9):1456. doi: 10.3390/vaccines10091456. PMID: 36146534; PMCID: PMC9504704.
130. Imran M, **Ortiz JR**, McLean HQ, Fisher L, O'Brien D, Bonafede M, et al. Relative Effectiveness of Cell-Based Versus Egg-Based Quadrivalent Influenza Vaccines in Adults During the 2019-2020 Influenza Season in the United States. *Open Forum Infect Dis*. 2022 Oct 12;9(10):ofac532. doi: 10.1093/ofid/ofac532. PMID: 36320195; PMCID: PMC9605706.
 131. Chaves SS, Nealon J, Burkart KG, Modin D, Biering-Sørensen T, **Ortiz JR**, Vilchis-Tella VM, Wallace LE, Roth G, Mahe C, Brauer M. Global, regional and national estimates of influenza-attributable ischemic heart disease mortality. *EClinicalMedicine*. 2022 Nov 18;55:101740. doi: 10.1016/j.eclinm.2022.101740. PMID: 36425868; PMCID: PMC9678904.
 132. Neuzil KM, Anderson EJ, Frenck RW, Frey SE, Walter EB, Rupp R, Rotrosen ET, Roupshael NG, Brady RC, Graham I, Schmader KE, Porterfield L, **Ortiz JR**, Swamy GK, Jeevan T, Sitaula R, Wegel A, Webby RJ, Bryant C, on behalf of the Influenza A/H5N8 Virus Vaccine Group. Safety and Immunogenicity of Influenza A/H5N8 Virus Vaccine in Healthy Adults: Durability and Cross-reactivity of Antibody Responses. *Clin Infect Dis*. 2023 Jan 5:ciac982. doi: 10.1093/cid/ciac982. Epub ahead of print. PMID: 36610728.
 133. **Ortiz JR**, Laufer RS, Brunwasser SM, Coulibaly F, Diallo F, Doumbia M, et al. Model-estimated impacts of pediatric respiratory syncytial virus prevention programs in Mali on asthma prevalence. *J Allergy Clin Immunol Glob*. 2023 May;2(2):100092. doi: 10.1016/j.jacig.2023.100092. PMID: 37215432; PMCID: PMC10193369.
 134. Laufer RS, Baral R, Buchwald AG, Campbell JD, Coulibaly F, Diallo F, Doumbia M, Driscoll AJ, Galvani AP, Keita AM, Neuzil KM, Sow S, Pecenka C, **Ortiz JR**, Fitzpatrick MC. Optimizing next-generation RSV prevention in Mali: A cost-effectiveness analysis of pediatric vaccination, maternal vaccination, and extended half-life monoclonal antibody immunoprophylaxis. *PLOS Glob Public Health*. 2023 May 5;3(5):e0001432. doi: 10.1371/journal.pgph.0001432. PMID: 37145993; PMCID: PMC10162555.
 135. Andrew M, Pott H, Staadegaard L, Paget J, Chaves SS, **Ortiz JR**, et al. Age differences in comorbidities, presenting symptoms and outcomes of influenza illness requiring hospitalization: a worldwide perspective from the Global Influenza Hospital Surveillance Network. *Open Forum Infect Dis*. 2023 May 7;10(6):ofad244. doi: 10.1093/ofid/ofad244. PMID: 37383245; PMCID: PMC10296081.
 136. Imran I, Puig-Barbera J, **Ortiz JR**, Bogdanov A, Bonafede M, Dudman D, et al. Relative effectiveness of the cell-based quadrivalent influenza vaccine in preventing cardiorespiratory hospitalizations in subjects aged 18–64 years during the 2019–2020 US influenza season. *Open Forum Infect Dis*. 2023 Jun 7;10(7):ofad304. doi: 10.1093/ofid/ofad304. PMID: 37496602; PMCID: PMC10368203.
 137. **Ortiz JR**, Bernstein DI, Hoft DF, Woods CW, McClain MT, Frey SE, et al. A Multi-Center, Controlled Human Infection Study of Influenza A (H1N1)pdm09 in Healthy Adults. *J Infect Dis*. 2023 Aug 11;228(3):287-298. doi: 10.1093/infdis/jiad021. PMID: 36702771; PMCID: PMC10420403.
 138. Fleming JA, Baral R, Higgins D, Khan S, Kochar S, Li Y, **Ortiz JR**, Cherian T, Feikin D, Jit M, Karron RA, Limaye RJ, Marshall C, Munywoki PK, Nair H, Newhouse LC, Nyawanda BO, Pecenka C, Regan K, Srikantiah P, Wittenauer R, Zar HJ, Sparrow E. Value profile for respiratory syncytial virus vaccines and monoclonal antibodies. 2023 Jul 6:S0264-410X(22)01212-9. doi: 10.1016/j.vaccine.2022.09.081. Epub ahead of print. PMID: 37422378.
 139. Fitzpatrick MC, Laufer RS, Baral R, Driscoll AJ, Feikin D, Fleming JA, Jit M, Kim S, Koltai M, Li Y, Li X, Nair H, Neuzil KM, Pecenka C, Sparrow E, Srikantiah P, **Ortiz JR**. Report of the WHO technical consultation on the evaluation of respiratory syncytial

- virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022. *Vaccine*. 2023 Sep 28:S0264-410X(23)01110-6. doi: 10.1016/j.vaccine.2023.09.040. Epub ahead of print. PMID: 37777450.
140. El Sahly HM, Yildirim I, Frey SE, Winokur P, Jackson LA, Bernstein DI, Creech CB, Chen WH, Rupp RE, Whitaker JA, Phadke V, Hoft DF, Ince D, Brady RC, Edwards KE, **Ortiz JR**, Berman MA, Weiss J, Wegel A, on behalf of the DMID 17-0090 Study Group. Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial. *J Infect Dis*. 2023 Jul 19:jjad276. doi: 10.1093/infdis/jjad276. Epub ahead of print. PMID: 37466221.
 141. Imran M, Puig-Barbera J, **Ortiz JR**, Lopez-Gonzalez L, Dean A, Bonafede M, et al. Relative Effectiveness of the MF59®-Adjuvanted Influenza Vaccine Versus High-Dose and Non-Adjuvanted Influenza Vaccines in Preventing Cardiorespiratory Hospitalizations During the 2019-2020 US Influenza Season. *Influenza Other Respir Viruses*. 2024 Apr;18(4):e13288. doi: 10.1111/irv.13288. PMID: 38644564.
 142. Singh K, Rubenstein K, Callier V, Shaw-Saliba K, Rupert A, Dewar R, et al.; for the ACTT-1 Study Group Members (**Ortiz JR** member). SARS-CoV-2 RNA and nucleocapsid antigen are blood biomarkers associated with severe disease outcomes that improve in response to remdesivir. *J Infect Dis*. 2024 Apr 24:jjae198. doi: 10.1093/infdis/jjae198. Epub ahead of print. PMID: 38657001.
 143. Ahrens KA, Janevic T, Strumpf EC, Nandi A, **Ortiz JR**, Hutcheon JA. Paid Family Leave and Prevention of Acute Respiratory Infections in Young Infants. *JAMA Pediatr*. 2024 Oct 1;178(10):1057-1065. doi: 10.1001/jamapediatrics.2024.3184. PMID: 39186259; PMCID: PMC11348083.
 144. Zar HJ, Cacho F, Kootbodien T, Mejias A, **Ortiz JR**, Stein RT, Hartert TV. Early-life respiratory syncytial virus disease and long-term respiratory health. *Lancet Respir Med*. 2024 Oct;12(10):810-821. doi: 10.1016/S2213-2600(24)00246-7. Epub 2024 Sep 9. PMID: 39265601.
 145. Cacho F, Gebretsadik T, Anderson LJ, Chappell JD, Rosas-Salazar C, **Ortiz JR**, Hartert T. Respiratory Syncytial Virus Prevalence and Risk Factors among Healthy Term Infants, United States. *Emerg Infect Dis*. 2024 Oct;30(10):2199-2202. doi: 10.3201/eid3010.240609. PMID: 39320243; PMCID: PMC11431910.
 146. Boudewijns B, Caini S, Del Riccio M, Nunes MC, Chaves SS, Andrew MK, **Ortiz JR**, Săndulescu O, Bresee JS, Burtseva E, Coulibaly D, Danilenko DM, Stolyarov K, Drăgănescu AC, Tanriover MD, Giamberardino HIG, Koul PA, Lopez-Labrador FX, McNeil SA, Mira-Iglesias A, Orrico-Sanchez A, Otieno NA, Ayugi J, Raboni SM, Spreeuwenberg P. Severity Scale of Influenza and Acute Respiratory Illness Hospitalizations to Support Viral Genomic Surveillance: A Global Influenza Hospital Surveillance Network Pilot Study. *Influenza Other Respir Viruses*. 2025 Mar;19(3):e70085. doi: 10.1111/irv.70085. PMID: 40045898; PMCID: PMC11883289.
 147. Nunes MC, Chauvel C, Raboni SM, López-Labrador FX, Andrew MK, Badar N, Baillie V, Bal A, Baral K, Baumeister E, Boutros C, Burtseva E, Coulibaly D, Cowling B, Danilenko D, Dbaibo G, Destras G, Dia N, Drăgănescu AC, Giamberardino HIG, Gomez-Camargo D, Josset L, Koul PA, Kyncl J, Laguna-Torres VA, Launay O, Nguyen LBL, McNeil S, Medić S, Mira-Iglesias A, Mironenko A, Nitsch-Osuch A, Orrico-Sánchez A, Otieno NA, Regue H, Ruiz-Palacios GM, Salah AB, Salman M, Săndulescu O, Simon V, Sominina A, Sordillo E, Tanriover MD, Unal S, van Bakel H, Vanhems P, Zhang T, Commaillé-Chapus C, Hunsinger C, Bresee J, Lina B, McCauley JW, **Ortiz JR**, Viboud C, Zhang W, Torcel-Pagnon L, Mahe C, Chaves SS. The Global Influenza Hospital Surveillance Network: A Multicountry Public Health Collaboration. *Influenza Other Respir Viruses*. 2025 Mar;19(3):e70091. doi: 10.1111/irv.70091. PMID: 40082217; PMCID: PMC11906252.

148. Ahrens KA, Hutcheon JA, Strumpf EC, Nandi A, **Ortiz JR**, Janevic T. Paid family leave and reduced acute respiratory infections in young infants: Does everyone benefit equally? *Am J Epidemiol*. 2025 Jun 9:kwaf124. doi: 10.1093/aje/kwaf124. Epub ahead of print. PMID: 40512650.
149. Deming ME, Toapanta FR, Pasetti M, Golding H, Khurana S, Hamouda T, Fattom A, Liang Y, Tennant SM, McGilvray MF, Bernal PJ, Oshinsky JJ, Datta S, Booth JP, Coughlan L, Neuzil KM, Costley CD, Kotloff KL, Sztein MB, **Ortiz JR**; rH5 Writing Group. An intranasal adjuvanted, recombinant influenza A/H5 vaccine primes against diverse H5N1 clades: a phase I trial. *Nat Commun*. 2025 Nov 6;16(1):9321. doi: 10.1038/s41467-025-64686-3. PMID: 41198655; PMCID: PMC12592354.
150. Lai J, Sobhani H, Coleman KK, Tai SS, Hong F, Sierra Maldonado I, Esparza Y, McPhaul KM, Zhu S, DeVoe DL, **Ortiz JR**, Chen S, Yellin T, Carreno JM, Krammer F, Cowling BJ, Gordon A, Chen WH, Srebric J, Milton DK; EMIT-2 Study Team. Evaluating modes of influenza transmission (EMIT-2): Insights from lack of transmission in a controlled transmission trial with naturally infected donors. *PLoS Pathog*. 2026 Jan 7;22(1):e1013153. doi: 10.1371/journal.ppat.1013153. PMID: 41499634; PMCID: PMC12799188.
151. Myint AP, Shirreff G, Baillie V, Bal A, Boutros CF, Burtseva E, Coulibaly D, Danilenko D, Dbaibo G, Destras G, Dia N, Drăgănescu AC, Giamberardino HIG, Komissarov AB, Koul PA, Laguna-Torres VA, LeBlanc JJ, Mira-Iglesias A, Mironenko A, Orrico-Sánchez A, Otieno NA, Săndulescu O, Simon V, Sominina A, Sordillo E, Tanriover MD, Teteriuk N, Unal S, Van Bakel H, Andrew MK, Bresee J, Lina B, López-Labrador FX, **Ortiz JR**, Raboni SM, Zhang W, Chaves SS, Cacciapaglia G, Josset L, Chauvel C, Nunes MC. Association of influenza viral genetic information with severity markers in patients hospitalised with influenza: multicentre retrospective cohort study. *BMJ Open*. 2026 Jan 8;16(1):e111643. doi: 10.1136/bmjopen-2025-111643. PMID: 41506775; PMCID: PMC13059944.
152. Chen WH, Barry EM, Toapanta FR, Pasetti MF, Sztein MB, Permala-Booth J, Tennant SM, **Ortiz JR**, Thomas C, McGilvray M, Roane L, Datar R, Liang Y, Levine MM. First-in-Human Evaluation of the Safety, Genetic Stability, and Immunogenicity of an Attenuated *Shigella flexneri* 2a Live Vector Expressing Enterotoxigenic *Escherichia coli* Antigens, Vaccine Strain CVD 1208S-122. *J Infect Dis*. 2026 Apr 18:jiag220. doi: 10.1093/infdis/jiag220. Epub ahead of print. PMID: 41999631.
153. Gilmore AC, Liang Y, Galbreath IM, Hobbs LK, LaRocco AM, Ludeman EM, Fitzpatrick MC, Friedman L, Warshawsky BF, Kwong JC, Neuzil KM, **Ortiz JR**. Indirect Influenza Vaccine Effectiveness Under Randomized Conditions: A Systematic Review and Meta-Analysis. *Clin Infect Dis*. 2026 Feb 27:ciag138. doi: 10.1093/cid/ciag138. Epub ahead of print. PMID: 41762145.
154. Tal-Singer R, McCreary G, Luttmann M, Williams S, Willard K, Wise R, **Ortiz JR**. Attitudes toward vaccines and antivirals for viral respiratory infections in a survey of US adults with chronic health conditions. *Vaccine*. 2026 Apr 2;77:128384. doi: 10.1016/j.vaccine.2026.128384. Epub 2026 Feb 20. PMID: 41722534.
155. Revilla AM, Raboni SM, Giamberardino HIG, Andrew MK, Badar N, Baillie V, Baumeister E, Burtseva E, Dbaibo G, Dia N, Drăgănescu AC, Koul PA, Simon V, Sordillo E, van Bakel H, Sominina A, Zhang T, López-Labrador FX, Mira-Iglesias A, Orrico-Sánchez A, Huang QS, Bresee J, **Ortiz JR**, Nunes MC, Chaves SS. Clinical Characteristics and Severity of Rhinovirus/Enterovirus-Associated Hospitalizations: A Multicountry Analysis

- From the Global Influenza Hospital Surveillance Network, 2017-2024. *Open Forum Infect Dis.* 2026 Mar 26;13(4):ofag146. doi: 10.1093/ofid/ofag146. PMID: 41929668; PMCID: PMC13043072.
156. Snyder BM, Riddell CA, Gebretsadik T, Ding T, Lee RL, Dupont WD, **Ortiz JR**, Pav V, Braciale TJ, Wu P, Hartert TV. Leukotriene modifying agent chemoprophylaxis for severe influenza illness: A multi-approach study. *Am J Epidemiol.* 2026 Apr 1:kwag072. doi: 10.1093/aje/kwag072. Epub ahead of print. PMID: 41921057.
 157. **Ortiz JR**, Kurup D, Kaufman AC, Ben Hamed S, LaRocco AM, Lyke KE, Litts SM, Datta S, Liang Y, McGilvray MF, Losignor JA, Oshinsky JJ, Palmer KV, Johnson-Mayo IPL, Scher G, Balakumar U, Chandwani A, Rapaka RR, Deming ME, Chua JV, Wirblich C, Chen WH, Neuzil KM, Pasetti MF, Schnell MJ. Immunogenicity of an adjuvanted, combination inactivated rabies-vectored Lassa fever vaccine in healthy adults: interim results of a first-in-human phase 1 trial. In press at *Nature Med.*

Non-peer-reviewed journal articles

1. **Ortiz JR** & Neuzil KM. The promise of maternal vaccination to prevent influenza in young infants. *Arch Pediatr Adolesc Med.* 2011 Feb;165(2):179-80. Epub 2010 Oct 4. PubMed PMID: 20921344.
2. Jacob ST, **Ortiz JR**, West E. Treatment of sepsis. *Lancet Infect Dis.* 2012 Oct;12(10):746. doi: 10.1016/S1473-3099(12)70227-X. Epub 2012 Sep 24. PubMed PMID: 23017362.
3. **Ortiz JR**. High rates of associated morbidity and mortality justify flu vaccination. *BMJ.* 2014 Dec 10;349:g7450. doi: 10.1136/bmj.g7450. PubMed PMID: 25499012.
4. **Ortiz JR**, Neuzil KM, Cooke CR. The authors reply. (Letter to the editor). *Crit Care Med.* 2015 Apr;43(4):e118. doi: 10.1097/CCM.0000000000000887. PubMed PMID: 25768367.
5. World Health Organization (Ortiz JR Editorial Board). Dengue vaccine: WHO position paper-July 2016. *Wkly Epidemiol Rec.* 2016 Jul 29;91(30):349-64. English, French. PubMed PMID: 27476189.
6. Hutcheon JA, Fell DB, Jackson ML, Kramer MS, **Ortiz JR**, Savitz DA, Platt RW. Hutcheon et al. Respond to "Maternal Influenza Immunization and Birth Outcomes". *Am J Epidemiol.* 2016 Dec 1;184(11):793-795. Epub 2016 Oct 26. PubMed PMID: 27784656; PubMed Central PMCID: PMC5152667.
7. World Health Organization (Ortiz JR Editorial Board). Tetanus vaccines: WHO position paper-February 2017. *Wkly Epidemiol Rec.* 2017 Feb 10;92(6):53-76. English, French. PubMed PMID: 28185446.
8. World Health Organization (Ortiz JR Editorial Board). Measles vaccines: WHO position paper-April 2017. *Wkly Epidemiol Rec.* 2017 Apr 28;92(17):205-27. English, French. PubMed PMID: 28459148.
9. Hutcheon JA, Fell DB, Jackson ML, Kramer MS, **Ortiz JR**, Savitz DA, Platt RW. THE AUTHORS REPLY. *Am J Epidemiol.* 2017 May 1;185(9):861-862. doi: 10.1093/aje/kww203. PubMed PMID: 28369158; PubMed Central PMCID: PMC5411673.
10. World Health Organization (Ortiz JR Editorial Board). Human papillomavirus vaccines: WHO position paper, May 2017. *Wkly Epidemiol Rec.* 2017 May 12;92(19):241-68. English, French. PubMed PMID: 28530369.
11. World Health Organization (Ortiz JR Editorial Board). Yellow fever vaccine: WHO position on the use of fractional doses-June 2017. *Wkly Epidemiol Rec.* 2017 Jun 23;92(25):345-50. English, French. PubMed PMID: 28643507.

12. World Health Organization (Ortiz JR Editorial Board). Hepatitis B vaccines: WHO position paper-July 2017. *Wkly Epidemiol Rec.* 2017 Jul 7;92(27):369-92. English, French. PubMed PMID: 28685564. doi:10.1016/j.vaccine.2017.08.024. Epub 2017 Aug 16. PubMed PMID: 28822645
13. **Ortiz JR**, Jackson ML, Hombach J. Announcing the Publication of a WHO Guide to the Design and Interpretation of Observational Influenza Vaccine Effectiveness Studies. *Clin Infect Dis.* 2017 May 23. doi: 10.1093/cid/cix339. [Epub ahead of print] PubMed PMID: 28535180.
14. World Health Organization (Ortiz JR Editorial Board). Diphtheria vaccine: WHO position paper-August 2017. *Wkly Epidemiol Rec.* 2017 Aug 4;92(31):417-35. English, French. PubMed PMID: 28776357.
15. Hutcheon JA, **Ortiz JR**. Re: Birth outcomes for Australian mother-infant pairs who received an influenza vaccine during pregnancy 2012-2014: The FluMum study. *Vaccine.* 2017 Aug 16;35(35 Pt B):4491. doi: 10.1016/j.Vaccine.2017.06.016. PubMed PMID: 28818440.
16. World Health Organization (Ortiz JR Editorial Board). Cholera vaccines: WHO position paper-August 2017. *Wkly Epidemiol Rec.* 2017 Aug 25;92(34):477-98. English, French. PubMed PMID: 28845659.
17. **Ortiz JR**. The challenge of vaccine policy-making with imperfect data. *Clin Infect Dis.* 2017 Oct 4. doi: 10.1093/cid/cix876. [Epub ahead of print] PubMed PMID: 29028972.
18. **Ortiz JR**. Implementation of maternal influenza immunization programs. *Vaccine.* 2018 Jun 14;36(25):3571. doi: 10.1016/j.vaccine.2018.01.039. PubMed PMID: 29801759.
19. **Ortiz JR**, Hombach J. Announcing the publication of the WHO immunological basis for immunization series module on influenza vaccines. *Vaccine.* 2017 Oct 14. pii: S0264-410X(17)31226-4. doi: 10.1016/j.vaccine.2017.09.010. [Epub ahead of print] PubMed PMID: 29042200.
20. **Ortiz JR**, Sugimoto JD, Neuzil KM, Halloran ME, Victor JC. Reply to Skowronski and De Serres. *Clin Infect Dis.* 2019 May 6. pii: ciz352. doi: 10.1093/cid/ciz352. [Epub ahead of print] PubMed PMID: 31056688.
21. **Ortiz JR**. The power of registry studies to inform maternal influenza vaccine policy and practice. *J Intern Med.* 2019 Oct;286(4):484-486. doi: 10.1111/joim.12954. Epub 2019 Aug 2. PMID: 31283055.
22. **Ortiz JR**, Hartert TV. The Role American Thoracic Society Healthcare Providers Have in Immunization. *Am J Respir Crit Care Med.* 2021 Apr 15;203(8):944-945. doi: 10.1164/rccm.202010-3990ED. PMID: 33606953; PMCID: PMC8048746.
23. **Ortiz JR**, Neuzil KM. The value of vaccine programme impact monitoring during the COVID-19 pandemic. *Lancet.* 2021 Nov 3:S0140-6736(21)02322-9. doi: 10.1016/S0140-6736(21)02322-9. Epub ahead of print. PMID: 34741819; PMCID: PMC8565930.
24. Mehrabadi A, Dodds L, MacDonald NE, Top KA, Benchimol EI, Kwong JC, Ortiz JR, Sprague A, Walsh LK, Wilson K, Fell DB. (2021). Association of Maternal Influenza Vaccination During Pregnancy With Early Childhood Health Outcomes. *Obstetrical & Gynecological Survey*, 76 (12), 717-718. doi: 10.1097/OGX.0000000000000987.
25. Hartert TV, **Ortiz JR**. The need for improved measurement-estimating the global burden of early childhood RSV disease. *Lancet.* 2022 May 19:S0140-6736(22)00623-7. doi: 10.1016/S0140-6736(22)00623-7. Epub ahead of print. PMID: 35598609.

Book chapters

26. **Ortiz JR**, Hauer KE. 2003. Night Calls. In: Shaw S, ed. *Hospitalist Handbook*. University of California, San Francisco.

27. **Ortiz JR**, Uyeki TM. 2006. Avian Influenza A (H5N1). In: Scheld WM, Craig WA, Hughes JM, eds. *Emerging Infections 7*. Washington, D.C.: American Society of Microbiology Press.
28. **Ortiz JR**, Uyeki TM. 2010–2017. Human infection with avian influenza A virus. In: Young C, ed. *BMJ Best Practice*. London, England: BMJ Press; 2010, 2012, 2013, 2014, 2017. Available at: <https://bestpractice.bmj.com/topics/en-gb/1190>
29. Dunning J, **Ortiz JR**, Uyeki TM. 2017–2019. Avian influenza H7N9 virus infection. In: Young C, ed. *BMJ Best Practice*. London, England: BMJ Press; 2017, 2019. Available at: <https://bestpractice.bmj.com/topics/en-gb/3000160>
30. Neuzil KM, **Ortiz JR**. 2016. Influenza Vaccines and Vaccination Strategies. In: Bloom BR, Lambert P-H, eds. *The Vaccine Book*, 2nd ed. Amsterdam: Elsevier. <http://dx.doi.org/10.1016/B978-0-12-802174-3.00021-7>.
31. **Ortiz JR**. 2016. Influenza. In: *International Travel and Health: Vaccination Requirements and Health Advice: Situation as on 2016*. Geneva: World Health Organization. Available at: http://www.who.int/ith/ITH_chapter_6.pdf.
32. **Ortiz JR**, West TE. 2020. Influenza. In: Broaddus VC, Ernst JD, King TE, Lazarus SC, Sarmiento KF, Schnapp LM, Stapleton RD, eds. *Murray & Nadel's Textbook of Respiratory Medicine*, 7th ed. Philadelphia, PA: Saunders Elsevier Press; 2021.
33. Monto AS, **Ortiz JR**. 2023–present. Seasonal influenza vaccination in adults. In: Hirsch MS, ed. *UpToDate*. Wolters Kluwer. Updated annually.
34. Levine A, Deming M, **Ortiz JR**. 2025. Influenza. In: Broaddus VC, Ernst JD, King TE, Lazarus SC, Sarmiento KF, Schnapp LM, Stapleton RD, eds. *Murray & Nadel's Textbook of Respiratory Medicine*, 8th ed. Philadelphia, PA: Saunders Elsevier Press. In press.

Other publications

1. Centers for Disease Control and Prevention (**Ortiz JR** lead author). CDC Recommends against the Use of Amantadine and Rimantadine for the Treatment or Prophylaxis of Influenza in the United States during the 2005-06 Influenza Season. CDC Health Alert Network. January 14, 2006. Available at: <http://www.cdc.gov/flu/han011406.htm>.
2. Pan American Health Organization (**Ortiz JR** lead author). Protocol for Influenza Surveillance. Pan American Health Organization. October 2006. Available at: www.paho.org/English/AD/DPC/CD/flu-snl-gpis.pdf.
3. World Health Organization (**Ortiz JR** member of writing committee). Clinical Management of Influenza and Other Acute Respiratory Illness in Resource-Limited Settings: Learning From the Influenza Pandemic (H1N1)2009. Geneva, Switzerland. Oct 2012. Available at: http://www.who.int/influenza/patient_care/clinical/858-WHOGIPReport_A4_WEB_FA.pdf.
4. World Health Organization (Ortiz JR team lead). Clinical Care for Severe Acute Respiratory Infection Toolkit. Geneva, Switzerland. Oct 2009. Updated 2022. Available at: <https://www.who.int/publications/i/item/clinical-care-of-severe-acute-respiratory-infections-tool-kit>
5. World Health Organization (**Ortiz JR** member of writing committee). WHO global technical consultation: Global Standards and Tools for Influenza Surveillance. Geneva, Switzerland, 8–10 March 2011. Available at: http://whqlibdoc.who.int/hq/2011/WHO_HSE_GIP_2011.1_eng.pdf.
6. World Health Organization (**Ortiz JR** member of writing committee). Global Epidemiological Surveillance Standards for Influenza (July 2012). Available at: <http://www.who.int/influenza/resources/documents/INFSURVMANUAL.pdf><http://www.who.int/influenza/resources/documents/INFSURVMANUAL.pdf>.

7. **Ortiz JR.** Vaccine Advisory Committee News. In: American College of Physicians Washington Chapter Governor's Newsletter. September 2012. Available at: http://www.acponline.org/about_acp/chapters/wa/nl-september2012.htm.
8. **Ortiz JR.** Vaccine Advisory Committee News. In: American College of Physicians Washington Chapter Governor's Newsletter. February 2013. Available at: http://www.acponline.org/about_acp/chapters/wa/nl-february2013.htm.
9. **Ortiz JR.** Vaccine Advisory Committee News. In: American College of Physicians Washington Chapter Governor's Newsletter. June 2011. Available at: www.washingtonacp.org/newsletter/june2011/june2011newsletter.htm.
10. **Ortiz JR.** Influenza-Associated Cystic Fibrosis Pulmonary Exacerbations [Thesis]. Seattle, Washington: UW, 2012.
11. World Health Organization (**Ortiz JR** member of writing committee). How to implement influenza vaccination of pregnant women: An Introduction Manual for National Immunization Programme Managers and Policy Makers (September 2016). Available at: <http://apps.who.int/iris/bitstream/10665/250084/1/WHO-IVB-16.06-eng.pdf>.
12. World Health Organization (**Ortiz JR** contributor). Recommendations on Antenatal Care for a Positive Pregnancy Experience. Geneva: WHO; 2016. Available at: <http://apps.who.int/iris/bitstream/10665/250796/1/9789241549912-eng.pdf>.
13. World Health Organization (**Ortiz JR** contributor). Labelling Information of Inactivated Influenza Vaccines for Use in Pregnant Women. Geneva: WHO; 2016. Available at: http://www.who.int/entity/biologicals/expert_committee/Label_after_ECBS_HK_28_Oct_2016.clean.pdf.
14. World Health Organization (**Ortiz JR** contributor). Flutool for planning and costing maternal influenza vaccination. Pilot Version 1.0. Geneva: WHO; 2016. Available at: <http://apps.who.int/iris/bitstream/10665/250087/1/WHO-IVB-16.07-eng.pdf>.
15. World Health Organization (**Ortiz JR** WHO lead). Evaluation of influenza vaccine effectiveness: a guide to the design and interpretation of observational studies. Geneva: World Health Organization; 2017. License: CC BY-NC-SA 3.0 IGO. Available at: <http://apps.who.int/iris/bitstream/10665/255203/1/9789241512121-eng.pdf>.
16. World Health Organization (**Ortiz JR** WHO lead). Preferred Product Characteristics for Next Generation Influenza Vaccines. Geneva: WHO; 2017. License: CC BY-NC-SA 3.0 IGO. Available at: <http://apps.who.int/iris/bitstream/10665/258767/1/9789241512466-eng.pdf>
17. World Health Organization (**Ortiz JR** WHO lead). The immunological basis for immunization series: module 23: influenza vaccines. Geneva: WHO; 2017 (Immunological basis for immunization series; module 23). Licence: CC BY-NC-SA 3.0 IGO. Available at: <http://apps.who.int/iris/bitstream/10665/259211/1/9789241513050-eng.pdf>
18. World Health Organization (**Ortiz JR** contributor). WHO public health research agenda for influenza: 2017 update. Geneva: WHO; 2017. Licence: CC BY-NC-SA 3.0 IGO. Available at: <http://apps.who.int/iris/bitstream/10665/259889/1/9789241513463-eng.pdf?ua=1>
19. Advancing Maternal Immunization (AMI) (**Ortiz JR** Member AMI Technical Expert Panel). Advancing RSV Maternal Immunization: A Gap Analysis Report. 2018. Available at: https://path.azureedge.net/media/documents/Advancing_RSV_Maternal_Immunization_A_Gap_Analysis_Report.pdf
20. PATH (**Ortiz JR** Coauthor). Maternal Influenza Immunization: Lessons from vaccine introduction and use in El Salvador. Seattle: PATH; 2016. Available at: https://path.azureedge.net/media/documents/CVIA_El_Sal_Mat_Flu_Imm_2018_rpt.pdf
21. PATH (**Ortiz JR** Coauthor). Maternal Influenza Immunization: Perceptions of decision-makers, health care providers, and the community in Malawi. Seattle: PATH; 2016.

- Available at: https://path.azureedge.net/media/documents/CVIA_Malawi_Maternal_Flu_Imm_Perceptions_publication.pdf
22. Panel on Immunization in HIV-Infected Adults and Adolescents (**Ortiz JR**, Panel Member). Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at: <https://aidsinfo.nih.gov/guidelines>
 23. PATH (**Ortiz JR** Member Technical Expert Panel). A Roadmap for Advancing RSV Maternal Immunization. Seattle: PATH; 2018.
 24. **Ortiz JR** and Deming M. The Rapid Clinical Development of SARS-CoV-2 Vaccines. *ATS Research News Quarterly*. March 6, 2021. Available at: https://www.thoracic.org/about/newsroom/newsletters/research-news-quarterly/resources/finalresearch_news-march-21.pdf
 25. World Health Organization (**Ortiz JR** Member of Technical Writing Group). Evaluation of COVID-19 vaccine effectiveness. 2021. Available at: <https://apps.who.int/iris/rest/bitstreams/1337417/retrieve>
 26. Williams SR, Driscoll AJ, LeBuhn HM, Chen WH, Neuzil KM, **Ortiz JR**. National Routine Adult Immunization Programs among WHO Member States: An Assessment of Health Systems to Deploy Future SARS-CoV-2 Vaccines. *medRxiv* 2020.10.16.20213967; doi: <https://doi.org/10.1101/2020.10.16.20213967>
 27. **Ortiz JR**, Robertson J, Hsu J-S, Yu SL, Driscoll AJ, Williams SR, Chen WH, Fitzpatrick MC, Sow S, Biellik RJ, Okwo-Bele J-M, Neuzil KM. The operational impact of deploying SARS-CoV-2 vaccines in countries of the WHO African Region. *medRxiv* 2020.08.13.20147595; doi: <https://doi.org/10.1101/2020.08.13.20147595>
 28. Lina B, Georges A, Burtseva E, Nunes M, Andrew MK, Ruiz-Palacios GM, Feng L, Kyncl J, Vanhems P, Ferdinands JM, **Ortiz JR**, Paget PG, and Reiner RC on behalf of the GIHSN. Complicated hospitalization due to influenza: Results from the Global Hospital Influenza Network for the 2017–2018 season, 16 June 2020, PREPRINT (Version 3) available at Research Square [<https://doi.org/10.21203/rs.3.rs-16799/v3>]
 29. Laufer RS, Baral R, Buchwald AG, Campbell JD, Coulibaly F, Diallo F, Doumbia M, Driscoll AJ, Galvani AP, Haidara FC, Keita AM, Neuzil KM, Sow S, Pecenka C, **Ortiz JR**#, Fitzpatrick MC#. Optimizing next-generation RSV prevention in Mali: a cost-effectiveness analysis of pediatric vaccination, maternal vaccination, and extended half-life monoclonal antibody immunoprophylaxis. *medRxiv* 2022.05.19.22275309; doi: <https://doi.org/10.1101/2022.05.19.22275309> (*#=Co-senior author*)
 30. **Ortiz JR**, Bernstein DI, Hoft DF, Woods CW, McClain MT, Frey SE, Brady RC, Bryant C, Wegel A, Frenck RW, Walter EB, Abate G, Williams SR, Atmar RL, Keitel WL, Rouphael N, Memoli MJ, Makhene MK, Roberts PC, Neuzil KM. A Multi-Center, Controlled Human Infection Study of Influenza A (H1N1)pdm09 in Healthy Adults. *medRxiv* 2022.09.27.22280383; doi: <https://doi.org/10.1101/2022.09.27.22280383>
 31. Gilmore A, **Ortiz J**. Pneumococcal Vaccines. *Am J Respir Crit Care Med*. 2024 May 15;209(10):P5-P7. doi: 10.1164/rccm.209i10p5. PMID: 38747567.
 32. Deming ME, Toapanta FR, Pasetti M, Golding H, Khurana S, Hamouda T, Fattom A, Liang Y, Tennant SM, McGilvray MF, Bernal PJ, Oshinsky JJ, Datta S, Permala Booth J, Coughlan L, Neuzil KM, Costley CD, Kotloff KL, Sztein MB, **Ortiz JR**, on behalf of the rH5 Writing Group. An intranasal adjuvanted, recombinant influenza A/H5 vaccine candidate induces broad priming against diverse influenza A/H5N1 virus clades in a phase I randomized trial in healthy adults. 05 March 2025, PREPRINT (Version 1) available at Research Square [<https://doi.org/10.21203/rs.3.rs-6059149/v1>]

33. Lai J, Sobhani H, Coleman KK, Tai SS, Hong F, Sierra Maldonado I, Esparza Y, McPhaul KM, Zhu S, DeVoe DL, Ortiz JR, Chen S, Yellin T, Carreno JM, Krammer F, Cowling BJ, Gordon A, Chen WH, Srebric J, Milton DK; EMIT-2 Study Team. Evaluating Modes of Influenza Transmission (EMIT-2): Challenges of a Controlled Human Influenza Virus Infection Transmission Trial (CHIVITT). medRxiv [Preprint]. 2025 May 1:2025.04.28.25326458. doi: 10.1101/2025.04.28.25326458. PMID: 40657316; PMCID: PMC12248172.
34. **Ortiz JR**, Kurup D, Kaufman AC, Ben Hamed S, LaRocco AM, Lyke KE, Litts SM, Datta S, Liang Y, McGilvray MF, Losignor JA, Oshinsky JJ, Palmer KV, Johnson-Mayo IPL, Scher G, Balakumar U, Chandwani A, Rapaka RR, Deming ME, Chua JV, Wirblich C, Chen WH, Neuzil KM, Pasetti MF, Schnell MJ. Immunogenicity of an adjuvanted, combination inactivated rabies-vectored Lassa fever vaccine in healthy adults: interim results of a first-in-human phase 1 trial. medRxiv. 2025;2025.10.16.25338178.

Published multimedia and datasets

1. Council of State and Territorial Epidemiologists (**Ortiz JR** member of writing committee). Rapid Response Training: The Role of Public Health in a Multi-Agency Response to Avian Influenza in the United States. 2007. Available at: www.cste.org/influenza/avian.asp.
2. World Health Organization (**Ortiz JR** team lead 2009-2010, member 2010-2018) WHO Clinical Care Severe Acute Respiratory Infection Training. 2009. Updated 2020. Available at: <https://openwho.org/courses/severe-acute-respiratory-infection>
3. World Health Organization (**Ortiz JR** project lead). Critical Care Training Short Course. Geneva: WHO; 2013. Available at: http://influenzatraining.org/static/toolkit/WHO_GIPCCare_CDRom_V3Master_June_2013/index.html.
4. **Ortiz JR**, 2018, "Traditional Cooking Practices and Preferences for Stove Features Among Women in Rural Senegal: Informing Improved Cookstove Design and Interventions", <https://doi.org/10.7910/DVN/FIWYJF>, Harvard Dataverse, V1.

INVITED SPEECHES

Local

1. HIV and migrant farm workers. Harvard AIDS Institute. Boston, MA. USA, October 21, 2001.
2. An update on avian influenza. Rollins School of Public Health, Emory University. Atlanta, GA. USA, November 2, 2005.
3. Human, avian, and pandemic influenza. Rollins School of Public Health, Emory University. Atlanta, GA. USA, April 6, 2006.
4. Pediatric influenza. Morehouse School of Medicine Pediatric Grand Rounds. Atlanta, GA. USA, November 16, 2006.
5. Risk of transmission of avian influenza A (H5N1). Vaseport Respiratory Conference. Whistler, British Columbia, Canada, February 25, 2008.
6. Novel influenza surveillance: can google obviate the need for public health infrastructure. Vaseport Respiratory Conference. Crystal Mountain, WA. USA, March 1, 2010.
7. Maternal Influenza Immunization: Translating Policy to Practice. Johns Hopkins School of Public Health Seminar. Baltimore, USA, March 28, 2017.
8. Severe Influenza Epidemiology and Global Vaccine Policy Making. Pulmonary Grand Rounds Conference. UMSOM. Baltimore, Maryland. October 30, 2017.
9. Immunization across the life-span. UMSOM, Department of Medicine Grand Rounds. Baltimore, Maryland, USA. 23 August 23, 2018.

10. Informing randomized clinical trials of RSV vaccination during pregnancy to prevent recurrent childhood wheezing. 2018 Frontiers in Vaccinology. UMSOM. Baltimore, Maryland. November 26, 2018.
11. A history of WHO influenza vaccine policy making: a case study of evidence-based public health practice. UMSOM. CVD Seminar. Baltimore, Maryland. March 11, 2019.
12. Informing randomized clinical trials of RSV vaccination during pregnancy to prevent recurrent childhood wheezing. 2018 Frontiers in Vaccinology. UMSOM. Baltimore, Maryland. November 26, 2018.
13. Preparing for COVID-19 vaccine deployment in developing countries. Pulmonary Grand Rounds. University of Maryland Medical Center. October 15, 2020.
14. Controlled Human Infection Models of Influenza Virus Infection. UMSOM, Department of Medicine Grand Rounds. Baltimore, Maryland, USA. February 9, 2022.
15. Influenza in the ICU. Pulmonary Grand Rounds. University of Maryland Medical Center. February 15, 2022.
16. The future of global influenza prevention and control. Public Health Seminar. University of Maryland College Park. January 17, 2024.
17. A First-in-Human Trial of a Rabies Virus-Vectored Lassa Fever Vaccine Candidate. 2024 Frontiers in Vaccinology. UMSOM. Baltimore, Maryland. October 28, 2024.
18. Controlled Human Infection Models for Influenza. Pulmonary Grand Rounds. University of Maryland Medical Center. November 4, 2024.
19. RSV Disease and Prevention in Adults. UMSOM, Department of Medicine Grand Rounds. Baltimore, Maryland, USA. January 16, 2025.

National

20. An update on avian influenza. The annual meeting of the American College of Osteopathic Internists. Orlando, FL. USA, October 23, 2005.
21. Case management of suspect influenza A (H5N1) in humans. Council of State and Territorial Epidemiologists Avian Influenza Rapid Response Training. Denver, CO. USA, February 6, 2007.
22. Development of novel tools to estimate the burden of influenza-associated critical illness. Robert Wood Johnson Harold Amos Medical Faculty Development Program Annual Meeting. New Orleans, LA. USA, October 5, 2011.
23. Valedictory speech. Harold Amos Medical Faculty Development Program. Atlanta, GA. USA, October 4, 2013.
24. Influenza vaccine for pregnant women: the challenges of translating research to practice. Visiting Scientist Lecture. CVD. University of Maryland. USA, August 30, 2016.
25. Maternal influenza immunization: A policy approach. 2017 Frontiers in Vaccinology. UMSOM. Baltimore, Maryland. December 13, 2017
26. Global Influenza Vaccine Policy: the Evolution of Evidence-Based Public Health Practice. International Vaccine Access Center, Johns Hopkins School of Public Health. Baltimore, Maryland. December 14, 2017.
27. LAIV Effectiveness: The Global View. Annual Conference on Vaccinology Research. Bethesda, USA. 25 April 2018.
28. Adult immunization in low-resource settings: preparing for COVID-19 vaccine deployment. Edith McGill Lectureship at Pulmonary Grand Rounds. Vanderbilt University Medical Center. September 18, 2020.
29. The Impact of Early Childhood RSV Disease and Prevention. Maternal RSV Vaccine Preparedness Quality and Innovation Collective Meeting. Baltimore, Maryland. October 8, 2024.
30. New Jersey Immunization Network Adult Immunization Conference. RSV Disease and Prevention Among Adults Living with Chronic Disease. October 30, 2024.

31. Providing Older Patients with the Information They Need. California Thoracic Society (CTS) Annual Educational Conference. March 21, 2025.

International

32. Global influenza surveillance. Pan-American Health Organization, Caribbean Epidemiology Center Influenza Surveillance Meeting. Washington, DC. USA, November 29, 2006.
33. Global overview of avian influenza. Pan American Health Organization, CDC Avian Influenza Surveillance and Grantees Workshop. Washington, DC. USA, February 1, 2007.
34. Pan American Health Organization, CDC generic influenza surveillance protocol. Pan American Health Organization, CDC Avian Influenza Surveillance and Grantees Workshop. Washington, DC. USA, February 1, 2007.
35. Pan American Health Organization, CDC Generic Influenza Surveillance protocol. Pan American Health Organization Southern Cone regional influenza surveillance workshop. Mar del Plata, Argentina, February 27, 2007.
36. Enhanced national influenza surveillance. Pan American Health Organization Southern Cone regional influenza surveillance workshop. Mar del Plata, Argentina, February 28, 2007.
37. Pan American Health Organization, CDC generic influenza surveillance protocol. Pan American Health Organization Andean regional influenza surveillance workshop. Lima, Peru, May 21, 2007.
38. Enhanced national influenza surveillance. Pan American Health Organization Andean regional influenza surveillance Workshop. Lima, Peru, May 22, 2007.
39. Objectives of influenza surveillance. WHO Global Influenza Surveillance Guideline Revision Workshop. Geneva, Switzerland, December 13, 2010.
40. Influenza immunization in pregnant women. South African Maternal Influenza Vaccination Trial Meeting of the Data and Safety Monitoring Board and Investigators. Johannesburg, South Africa, February 21, 2011.
41. Influenza surveillance strategy. WHO Consultation on Global Tools and Manual for Influenza Surveillance. Geneva, Switzerland, March 8, 2011.
42. Influenza burden of disease in pregnancy. WHO Workshop on Influenza Burden of Disease and Economic Analysis. Bali, Indonesia, June 5, 2012.
43. Influenza vaccine prioritization. Afriflu Influenza Symposium. Cape Town, South Africa, November 8, 2012.
44. Maternal immunization. Fondation Mérieux international expert meeting on influenza vaccines as a tool to estimate the burden of severe influenza. Annecy, France, November 30, 2012.
45. Priority risk factor research for influenza burden of disease. WHO Informal Consultation on Influenza Disease Burden, Geneva, Switzerland, December 6, 2012.
46. LAIV clinical trials. PATH Meeting on LAIV Vaccine Trials in Infants and Young Children. Washington, DC. USA, July 9, 2013.
47. Influenza vaccine effectiveness. Meeting of the Partnership for Influenza Vaccine Introduction. Decatur, Georgia. USA, December 3, 2013.
48. Maternal influenza immunization. Influenza Vaccine Supply International Task Force Meeting of the International Federation of Pharmaceutical Manufacturers & Associations. Geneva, Switzerland, February 19, 2014.
49. Influenza vaccine effectiveness and WHO policy development. Meeting to develop guidance for field evaluation of influenza vaccine effectiveness. Geneva, Switzerland, February 22, 2014.

50. WHO Initiative for Vaccine Research. WHO Meeting with International Partners on Prospects for Influenza Vaccine Technology Transfer to Developing Country Vaccine Manufacturers. Dubai. United Arab Emirates, March 25, 2014.
51. Influenza vaccine safety. Training Workshop on Adverse Events Following Immunization (AEFI) Causality Assessment and Communication Capacity Building for Immunization. Manila, Philippines, May 12, 2014.
52. Influenza vaccine implementation research. Ad-Hoc IVIR-AC Working Group Meeting. Geneva, Switzerland, June 17, 2014.
53. Maternal immunization. WHO Consultation on influenza vaccines for pregnant and lactating women: Clinical data requirements for product labelling. Geneva, Switzerland, July 15, 2014.
54. Introductions, meeting procedures, and rationale. WHO meeting to develop Brighton collaboration definitions for events of special interest for monitoring and evaluation of immunization in pregnancy. Geneva, Switzerland, July 24, 2014.
55. Influenza vaccines. Influenza Vaccine Supply International Task Force Meeting of the International Federation of Pharmaceutical Manufacturers & Associations. Geneva, Switzerland, September 24, 2014.
56. Maternal influenza immunization. Meeting of the Global Advisory Group on Vaccine Safety Pregnancy Sub-Group. Geneva, Switzerland, September 29, 2014.
57. Influenza vaccines. Influenza Vaccine Supply International Task Force Meeting of the International Federation of Pharmaceutical Manufacturers & Associations. Geneva, Switzerland, February 25, 2015.
58. Maternal immunization. Technical Consultation on Maternal Influenza Immunization Evidence and Implementation. Geneva, Switzerland, March 25, 2015.
59. Implementation research gaps for furthering maternal immunization. Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE). Geneva, Switzerland, April 16, 2015.
60. Endpoints for safety monitoring during pregnancy and early childhood. Meeting of the Global Advisory Group on Vaccine Safety Pregnancy Sub-Group. Geneva, Switzerland, May 18, 2015.
61. Influenza. WHO Product Development for Vaccines Advisory Committee (PDVAC) meeting. Geneva, Switzerland, September 09, 2015.
62. WHO agenda on maternal immunization. WHO working group meeting on the development of guidelines on labelling influenza vaccines intended to be used in pregnant women. Geneva, Switzerland, September 24, 2015.
63. The effect of maternal influenza and influenza vaccination on the developing foetus: the need for evidence. Technical Consultation on the Effect of Maternal Influenza and Influenza Vaccination on the Developing Foetus. Montreal, Canada, September 30, 2015.
64. H1N1 vaccine and narcolepsy. Meeting of the Global Advisory Committee on Vaccine Safety. Geneva, Switzerland, December 3, 2015.
65. Influenza vaccines. Influenza Vaccine Supply International Task Force Meeting of the International Federation of Pharmaceutical Manufacturers & Associations. Geneva, Switzerland, February 24, 2016.
66. WHO agenda on maternal immunization. WHO informal consultation on labelling information of influenza vaccines intended to be used for pregnant women. Geneva, Switzerland, April 4, 2016.
67. WHO agenda on maternal immunization. WHO Consultation on RSV Vaccine Development. Geneva, Switzerland, April 25, 2016.
68. Influenza. WHO Product Development for Vaccines Advisory Committee (PDVAC) meeting. Geneva, Switzerland, June 9, 2016.

69. WHO efforts to promote next-generation influenza vaccines. Eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses. Chicago, USA, August 23, 2016.
70. Influenza vaccines. Influenza Vaccine Supply International Task Force Meeting of the International Federation of Pharmaceutical Manufacturers & Associations. Geneva, Switzerland, September 28, 2016.
71. Emerging issues with influenza vaccine effectiveness. ADVAC Alumni meeting. Geneva, Switzerland, October 18, 2016.
72. Vaccination Policies and Vaccine Programmatic Considerations in Risk Groups. Third WHO Consultation on Global Action Plan for Influenza Vaccines (GAP III). Geneva, Switzerland, November 15, 2016.
73. Towards the Future: Preferred Product Characteristics' Needs and Gaps. Third WHO Consultation on Global Action Plan for Influenza Vaccines (GAP III). Geneva, Switzerland, November 16, 2016.
74. Knowledge gaps related to LAIV, repeated influenza vaccination, and vaccinating pregnant women. Consultation for Updating WHO Public Health Research Agenda for Influenza: Meeting of the Technical Working Groups. Geneva, Switzerland, December 6, 2016.
75. Influenza Vaccines for Pregnant Women: the Challenges of Translating Policy to Practice. Centers for Disease Control and Prevention. Atlanta, USA, January 11, 2017.
76. WHO Immunization Policies for the Elderly. WHO Meeting on Immunization in the Elderly. Geneva, Switzerland, March 22, 2017.
77. Report of the WHO Taskforce to Evaluate Influenza Data to Inform Vaccine Impact and Economic Modelling. Gavi, the Vaccine Alliance. Geneva, Switzerland, May 05, 2017.
78. Influenza vaccine development: WHO recommendations for vaccine developers. Universal Flu Vaccine workshop, European Commission, Brussels, Belgium. June 14, 2017.
79. Current controversies in maternal influenza immunization research and their implications for global health policy-making. Symposium on methodological challenges of studying perinatal outcomes following vaccination in pregnancy: A case study on influenza Vaccine. Society for Epidemiologic Research Annual Meeting. Seattle, Washington. June 21, 2017.
80. Sample size estimation for RSV vaccine prevention of asthma/recurrent wheeze. WHO RSV vaccine technical advisory group meeting. Málaga, Spain. November 29, 2017.
81. Immunization across the life-span-What will it take? A global perspective. World Vaccine Congress, Washington DC, 2 April 2018.
82. Influenza Vaccination: How Collaboration and Advocacy Can Increase Uptake. International Federation of Aging Meeting on Vaccination and At-Risk Population of Adults with Heart and Lung Conditions. Stockholm, Sweden. 12 October 2018.
83. Immunization across the life-span. European Centres for Disease Control Scientific Seminar Series. Stockholm, Sweden. 19 October 2018.
84. Meeting on Methodological Considerations and Measurement of Respiratory Sequelae Associated with RSV Infection. WHO. Geneva, Switzerland. February 12, 2019.
85. Prioritization of Prevention-Global Priorities. Immunisation for Life Summit. Washington DC. June 5-6, 2019.
86. Benefits of influenza vaccination to older adults from a global perspective. New York, NY. End Immunisation Inequality toward Healthy Ageing Event at the United Nations. October 11, 2019.
87. A life-course and inclusive approach to vaccination strategies. International Pharmaceutical Federation (FIP) Webinar: The value of vaccines for society and special populations. September 14, 2020.

88. Immunisation for All Ages Webinar Series: Driving Policy to Action. October 8, 2020
89. Adult immunization in low-resource settings: preparing for COVID-19 vaccine deployment. Edith McGill Lectureship at Pulmonary Grand Rounds. Vanderbilt University Medical Center. September 18, 2020.
90. Fighting COVID-19: Clinical Trials, Vaccines, and Global Response. American Thoracic Society International Conference. May 14, 2021.
91. COVID Vaccine and the Respiratory Patient: How Does It Work, What to Expect? American Thoracic Society Meet-the-Experts Roundtable. May 15, 2021.
92. Moderator, WHO Meeting to Assess RSV Prevention Cost Effectiveness in Low- and Middle-Income Countries. April 6-7, 2022
93. Moderator, Vaccines and Global Health. GSK Vaccine Virtual Days. March 29, 2023
94. The Importance of Vaccines and Immunization to Respiratory Health. American Thoracic Society International Conference. May 22, 2023.
95. Practical Aspects of Vaccination. American Thoracic Society Public Advisory Roundtable (PAR). November 8, 2023.
96. Panelist, Defining Success Using CHIVIM in Vaccine Development. National Institute of Allergy and Infectious Diseases (NIAID) Controlled Human Influenza Virus Infection Model Studies: Current Status and Future Directions for Innovation. November 13-14, 2023.
97. Preventing RSV: Providing Older Patients With The Information They Need. American Thoracic Society International Conference. May 20, 2024.
98. Toward a Universal Flu Vaccine. American Thoracic Society International Conference. May 20, 2024.
99. A Phase 1 Randomized, Placebo Controlled, Safety, Tolerability, and Immunogenicity Study of Two Doses of Intranasal Recombinant H5 Influenza Vaccine with and without Nanoemulsion Adjuvant Followed by One Boosting Dose of Intramuscular Influenza A (H5N1) Vaccine. NIAID CIVICs Webinar Series. June 6, 2024.
100. 2024 CVD CIVICs Year in Review. NIAID CIVICs Annual Meeting. August 5, 2024.
101. Panel discussion. CIVICs Clinical Goals. NIAID CIVICs Annual Meeting. August 5, 2024.
102. Phase I Trial of Mucosal Adjuvanted Recombinant H5 Vaccine Followed by Parenteral H5N1 Boost. BARDA Influenza & Emerging Infectious Diseases Division (IEIDD) Monthly Seminar. August 15, 2024.
103. The Impact of Early Childhood RSV Disease and Prevention. American Medical Group Association Maternal RSV Vaccine Preparedness Quality and Innovation Collective Meeting. October 8, 2024.
104. Chair. ATS Vaccine Initiative: Health System Partner Learning Session. American Thoracic Society International Conference. May 17, 2025.
105. What We Do and Don't Yet Know About the Potential of Vaccines to Prevent Long-Term Respiratory Morbidity. American Thoracic Society International Conference. May 19, 2025.
106. Scientific Symposium Chair. Long-Term Consequences of Respiratory Viral Infections and Chronic Pulmonary Diseases: Long-Covid, Asthma, ILD and Lung Transplant. American Thoracic Society International Conference. May 21, 2025.
107. Overview of CIVICs Clinical Core. CIVICs Annual Meeting; Durham, NC; August 2025.
108. Indirect Influenza Vaccine Effectiveness Under Randomized Conditions: A Systematic Review and Meta-Analysis. NIAID CIVICs Webinar Series. April 2, 2026.
109. The Evolving Adult Respiratory Vaccine Landscape and Multi-Society Vaccine Policy Harmonization Efforts. ATS Vaccine Initiative Pulmonary Vaccine Toolkit Pre-Workshop Virtual Meeting. May 12, 2026.